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Research on aging has been invigorated by recent findings suggesting certain 
mutations in various invertebrate models (yeast, worms, and flies) can slow down aging 
and improve healthspan. Reactive Oxygen Species (ROS) production and manipulation 
of the nutrient-sensing [mammalian (originally) or mechanistic target of rapamycin] 
mTOR signaling pathway have all been linked to aging and age-related diseases. Thus, 
identifying ways to interfere in these pathways may represent a promising avenue to 
increase longevity and improve healthspan in mammals. Fullerenes are a class of 
nanomaterials best known for their ability to significantly extend mammalian lifespan 
and cognitive function as shown in both mice and rats. Thus, the goal of this proposal is 
to determine possible mechanisms of how fullerenes extend lifespan focusing on mTOR 
signaling pathways and anti-oxidant capabilities to slow down aging and improve 
healthspan. 
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CHAPTER I 
INTRODUCTION 
 
Fullerenes have been regarded as a unique approach to alleviate age-associated 
diseases, due to their high affinity towards free radicals [1-3].   Fullerene’s ability to 
efficiently scavenge free radicals,  without being consumed is attributed to its numerous  
conjugated double bonds and lowest unoccupied molecular orbital (LUMO) [2].  
Previous studies have reported the fullerene derivative C3 (C60-tris malonic acid) acts as a 
superoxide dismutase mimetic (SOD) [4], polyhydroxylated C60 molecules provided 
neuroprotection in cultured cortical neurons [5], and C70-tetraglycolic acid (TGA) 
potential as a therapeutic application for asthma and arthritis in mast cells.  
Published reports have linked many age-related diseases to the mammalian target 
of rapamycin (mTOR) pathway that are critical to age-associated diseases and 
impairment of function can impact healthspan.  Our lab has established that fullerene 
derivatives C3
 , ALM (a liposome encapsulated C70 fullerene) and TGA have the potential 
to alleviate age-related diseases such as asthma, arthritis and atherosclerosis [6-9] as a 
novel therapeutic  to improve the aging body and overall healthspan.  The significance of 
this research is to assess TGA anti-aging effects in an ex vivo human skin model, which 
has sparked our interest in nanomaterials and its impact on biological aging.   
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CHAPTER II 
REVIEW OF LITERATURE 
 
II. 1 Skin and Aging 
 Aging research has stimulated innovation in developing novel strategies to 
investigate the natural biological process of aging.  A process that has been attributed to 
reactive oxygen species (ROS) accumulation in a biological system that was proposed by 
Denham Harman in 1956 [10], which led to his establishment of the mitochondrial free 
radical theory of aging [11].  The free radical theory of aging states that cells age due to 
the accumulation of free radicals over time [10].  Therefore, accumulation of free radicals 
result in degradation of a biological system, but the contradictory nature of this theory is 
also in question.  For example, ROS production extending lifespan in S. cerevisiae by 
Mrg19 depletion [12]; exercise-induced ROS production inducing antioxidants, DNA 
repair and protein degrading enzymes and resulting in decreases in oxidative stress-
related diseases and retardation of the aging process [13]; and reported increased defense 
mechanisms prolong lifespan [14, 15].   
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                                    Figure 1. Illustration showing the oxygen molecule and generation  
                                    of free radicals. 
                                    Source: http://www.clevelandclinic.org/reproductiveresearchcenter 
    
                                         
                      
 If the free radical theory of aging can be both beneficial and detrimental, at this 
juncture, skin the largest organ in the body, constantly exposed to both intrinsic and 
extrinsic insults can be classified as a large producer of free radicals and optimal model 
for aging research.  Intrinsic aging is defined as physiological changes (genetics, 
hormone imbalance, or metabolic reactions) that are uncontrollable and extrinsic aging, 
to some extent, can be categorized as sun and toxin exposure, diet, pollutions and overall 
lifestyle choices [16, 17].   
In its entirety, the skin is comprised of three distinctive layers: epidermis, 
hypodermis, and dermis.  Here we are focusing on two layers: epidermis and dermis.  The 
epidermis is the outermost layer providing the most protection against UV exposure 
(stratum corneum), provides mechanical resistance, and immune surveillance [18].    
Keratinocytes form the outermost barrier of the skin and react against insults by 
mediating pro-inflammatory mediators to elicit an immune response.  Langerhans are 
antigen presenting immune cells (dendritic cells), originating from skin localized Ly-6C 
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monocyte precursors that induce immune response or tolerance; induction of 
hypersensitivity, and pathogenesis of chronic inflammatory skin disorders [19-21]. 
Melanocytes function primarily as photoprotection against DNA damage through 
melanin production; cross-talk between different signaling pathways to maintain skin 
homeostasis and actively secretes immunological molecules (i.e. IL-10, IL-1α, TNF-α,  
TGF-β, and nitric oxide)  [22].  Merkel cells are associated as a mechno-receptor and 
paracrine secretion in fetal development and adult homeostasis [23-25].   
Directly below the epidermis is the dermis, providing a scaffold for strength and 
support.  While the dermis is a thick layer of elastic and fibrous tissue, it also contains 
nerve endings, to aid in stress and strain detection.  This layer gives elasticity to the 
integument to resist wrinkling, sagging, and distortion.  Fibroblasts are the dominant cell 
type producing collagen, elastin, glycosaminoglycans, and various proteins in the dermal 
extracellular space [26].  Fibroblasts have been extensively studied in aging research 
ranging from organization of the cytoskeleton structure and senescent cells inability to 
replicate in humans [27]; improved functional and survival ability in mild heat shock 
treatment in vitro  [28]; protection by mitochondria targeted antioxidants from 
endogenous oxidative damage in friedrich ataxia fibroblasts [29]; as well as safety 
evaluation studies using fullerenes for skin irritation assessment in cosmetic applications 
[30].    
Macrophages play a role in innate immunity, in most tissues, their phagocytic 
properties are associated with initiating inflammatory response that recruits neutrophils 
and natural killer cells, regulate maturation, differentiation, and migration of dendritic 
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cells.  The impact of macrophages on innate immunity and aging can be used in 
identifying endogenous and exogenous “danger” signals emitted from damaged tissues 
[31, 32]. Macrophages have been used as an in vitro model for inflammation and 
nanomaterial research.  For example, exposure to fullerenes induced apoptosis by 
changing mitochondrial membrane potential  and decreasing cell viability [33]; and  
macrophages/Kupffer cells treated with dihydroquercin suppressed concanavalin A 
activity in a hepatitis mouse model enhancing heme-oxygenase-1 and MAPK/Nrf2 
antioxidant signaling [34].  C60 treatment have been shown to modify Th2 to Th1 
cytokine production and repair skin barrier function in a mice model of atopic dermatitis 
[35].   
Nanoparticles have been used as vehicles for drug delivery for enhanced 
bioavailability and skin penetration for deposition of biologically active ingredients [36, 
37] and control over compound release to improve efficacy in many skin formulations 
[37, 38].  For example, alginate, a low cost and biodegradable polymer is ideal for 
encapsulating antimicrobial plant extract for skin applications [39].  Trans-resveratrol 
loaded solid lipid nanoparticles penetrated the skin up to 45% after 24 hours, resulting in 
more tyrosinase inhibition over kojic acid and revealed non- toxic effects in keratinocytes 
[40],  Efficacy of  low dose nanoparticles on aging skin preserved spindle shape 
elongation, characteristics of young fibroblasts as seen using electron microscopy [41].  
Efficacy and safety studies are common practices used to create safety profiles 
surrounding short and long term effects of nanoparticles to determine risk assessment of 
chemicals, toxins, and nanomaterials through skin absorption [42].  
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II. 2 Fullerenes as Antioxidants 
Carbon based nanoparticles, fullerenes are carbon allotropes identified as ROS 
scavengers and nano-antioxidants for their potent antioxidant abilities in vitro.   Water 
soluble derivative fullerenes have been designed as effective antioxidants in biological 
systems to reduce free radical damage to biomolecules.  Several fullerene derivatives 
have been identified as neuroprotective  [43], therapeutic treatments against allergic 
diseases [44], inhibitors of inflammatory arthritis [7] and gene and drug delivery carriers 
[45, 46].  This notion has been investigated extensively with C60 fullerenes, based on their 
lowest unoccupied molecular orbit (LUMO) and ability to accept up to six electrons has 
made them suitable electron acceptors [47].  In addition to their knack to react with 
numerous free radicals without being consumed [2].  These same predictions were made 
for C70 with their spherical shape and potential to counteract the formation of superoxide 
anion, while a 100% efficiently is sensitized by C60, C70 sensitizes only  ~81%, in the 
presence of molecular oxygen [48].   
The increased focus on nanomaterials and human health has become an important 
research element for understanding cellular and tissue influences.   Reports on fullerenes 
have incurred favorable and unfavorable support with regard to the usefulness and 
therapeutic applications of functionalized fullerenes.  Many rely on synthesis methods 
and chemicals used to produce these functionalized nanomaterials result in assessment of 
cellular effects due to the biological activity of fullerenes.  Acid-treated single walled 
carbon nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs) down-
regulated adhesion related genes and perturbing physiological functions of actin filaments 
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of NIH 3T3 cells and human dermal fibroblasts [49].  Hone and colleagues reported C70-
medium dispersion induced intracellular ROS levels, however, pre-treatment with 
antioxidants prevented intracellular oxidative stress in human keratinocytes [50], 
supporting the notion of a synergistic effect between C70 and antioxidants.   
Interaction of C60 or C70 fullerenes with organic solvents can contribute to ROS 
generation in activated macrophages, as indicated through proinflammatory cytokines.  
Modulation of pro-inflammatory cytokines, tumor necrosis factor- alpha (TNF-α) was 
potentiated upon exposure to tetrahydrofyran(THF/nC60/C70) fullerenes causing increased 
apoptosis/necrosis, however, polyhydroxylated (C60/C70 (OH)n) fullerenes reduced TNF-
α expression and mitochondrial depolarization.  The dichotomy of these fullerenes 
provides the basis of their use in TNF-α based cancer therapy or deterrence against 
uncontrolled tissue damage [51].  The unique chemical and physical properties of 
fullerenes can contribute to beneficial or adverse effects in biological systems, due to 
their exploitation using innumerable side chain configurations [52, 53].     
Nanotechnology’s limitless possibilities have introduced compelling candidates, 
but as humans are the end users for most, if not all applications, these innovations can be 
challenging to the dermal immune system.   To better understand these challenges, well 
designed studies evaluating innate immunity and ROS derived organelles facilitate 
closing the knowledge gap supporting longevity and health span research.   
Innate immune cells, such as mast cells have been used as proinflammatory mediators in 
response to immunological and physico-chemical impetuses [7] [54, 55].  Water-soluble 
fullerenes, dubbed as “radical sponges” utilize electrochemical properties to react with 
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tissue damaging superoxide (O2
•-) and hydroxyl (•OH) radicals [51, 56].  Fullerenes, 
reactive oxygen species modulating agents are ideal interference against TNF-α mediated 
cell and tissue death [51].   Treatment with C60 fullerene, C3 attenuated age associated 
oxidative stress, improved cognitive function and extended lifespan in mice [57].  In a 
report by Hwang and Mauzerall, fullerenes electron-transfer capabilities have made them 
ideal to mediate transmembrane electron transport across lipid bilayer membranes [58].   
Research has taken into consideration fullerene toxicity, adsorption, distribution, 
metabolism and elimination based on functionalization of moieties for various sized 
fullerenes.  Fullerene derivatives have increased biological application compared to 
underivatized fullerenes due to their insolubility and potential for aggregation [59].  
Exploitation of their small size, large surface area, and affinity to react with numerous 
superoxides without being destroyed has been advantageous as an antioxidant [2]. C70 
fullerenes are composed of 70 carbon atoms with a spherical shape made of 25 hexagons 
and 12 pentagons, its antioxidant property has contributed several double bonds and low 
lying unoccupied molecular orbit allowing up to six electrons to be consumed [60].   
Efficacy of fullerenes and its antioxidant properties are not well understood and 
an in-depth investigation of mechanisms driving free radical sequestering, in complex 
biological systems are necessary for improvements in human health. 
II. 3  Mechanisms of Fullerenes  
Future improvements of lifespan and healthspan could be supported through 
nanoparticle-based immunostimulatory moieties activating in safe and efficacious 
combinations with stress response pathway systems.  Ideally, using nanotechnology to 
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advance aging research could aid in modulating ROS production while maintaining 
feasibility and safety to improving overall human health in biomedical applications.  
Studying molecular mechanisms underlying fullerenes and mTOR signaling pathways 
can potentially affect aging by means of altering dermal structure and function.   
Interactions have been investigated through the use of whole transcriptome 
methodologies  for gene expression modulation after treatment with functionalized 
fullerenes along the mTOR pathway [61].  Fullerenes provide a promising opportunity 
for novel therapies as inhibitors in cancer therapy [62, 63] , allergic diseases [44], and 
arthritis [7].   
Our lab has reported possibility for C70-I (myo-inositol) functionalized fullerenes 
as an alternative therapy for steroid resistance asthmatics via inhibition of inflammatory 
mediators in mast cells.  This study reinforced the effects fullerenes have on signaling 
pathways and modulating immune responses instigated by conventional treatments [64] 
and the emergence of fullerenes yielding results promising for current and future 
prospects to ease deleterious side effects of current treatments. 
Mechanistic target of rapamycin is a serine/threonine kinase belonging to a family 
of phosphatidylinositol 3’ kinase related kinase (PIKK), a signaling pathway regulating 
cellular growth, proliferation, survival, and motility, as well as protein synthesis and 
transcription.  The activation of mTOR by PI3K, an upstream regulatory, activating AKT 
via phosphorylation [61]. Originally discovered through a study using rapamycin, an 
immunosuppressant and anti-tumor drug, its effect on inhibiting mTOR signaling 
pathway has been associated in dysregulation of human diseases, such as cancer, 
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diabetes, synaptic plasticity, memory, learning, and aging [65-67].  The mTOR pathway 
consists of two complexes: mTOR Complex 1 (mTORC1) known to control autophagy, 
G1 cell cycle progression, and protein synthesis; and mTOR Complex 2 (mTORC2) is 
involved in regulating cytoskeletal structure through f-actin polymerization [68-70].   
Both mTORC1 and mTORC2 contain components of Deptor (DEP-domain 
containing mTOR-interacting protein) which inhibits kinase activity [71]; Tel 2 (telomere 
maintenance 2) and Tti1 (TELO2-interacting protein 1) form a complex to stabilize PIKK 
proteins and assembly of mTOR complex to maintain activities [72]; while mLST8 
(mammalian lethal with sec-13), also known as GβL, function is unclear in mTORC1, but 
maintains kinase activity in mTORC2 [66].  The protein Raptor (regulatory associated 
protein of mTOR) has a positive role on mTOR activity and is thought to act as a 
scaffold, binding multiple contact points and phosphorylation of downstream components 
(SGK1 and 4E-BP) to mTOR[67], as evidenced by knockdown studies using RNAi in 
mammalian cells [73].  PRAS40 (proline-rich AKT substrate 40 kDa) an interacting 
partner with raptor, negatively regulating mTORC1 kinase activity.  This association is 
attenuated by insulin or amino acids, bringing about dissociation of PRAS40 and 
mTORC1, due to phosphorylation [74] at protein components of mTORC1.   
 The other functional complex mTORC2, consists of similar proteins (DEPTOR, 
TEL2, Tti1 and mLST8), containing Rictor, a protein component essential for mTORC2 
activity.  A study conducted by Lammin et al [75] provided evidence that deletion of 
Rictor decreased lifespan in male mice, not females.  The protein mSIN1 (mammalian 
stress-activated protein kinase interaction protein 1) stabilizes the mTORC2 complex 
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through specificity with SGK-1 (serum glucocorticoid-induced protein kinase 1), PKB 
(protein kinase B/Akt), and PKC (protein kinase C), while Protor-1/PRR5 (Proline Rich 
Protein 5) is not required for activity [76] and does not bind nor sensitive to FKBP12-
rapamycin complex[77, 78].  Although, little is known about mTORC2 role in aging and 
age-related pathologies; it is known that phosphorylation of the hydrophobic regulatory 
region of PKB, SGK, and a few PKCs can promote cell survival.  Furthermore, 
cytoskeleton and cell motility is regulated by small Rho GTPases, and Paxillin within 
mTORC2 complex [79].  Activation of oncogenes PI3K, PKB, and Ras or inhibition of 
PTEN or p53 can dysregulate cellular metabolism and survival, therefore leading to age 
related pathologies.   
The FKBP12 rapamycin complex is necessary for binding to mTOR, through the 
FKBP12 rapamycin binding domain (FRB).  This ternary protein containing FKBP12 is a 
rapamycin-induced complex required for cell cycle progression and growth mediated by 
rapamycin.  Any mutation (point) can lead to FKBP12 rapamycin binding domain 
resistance to mTOR, particularly by modification of the mTORC1 structure [66, 68]. 
  Cellular processes regulating proliferation, growth, and metabolism can be traced 
to mTOR signaling pathway controlled via mTORC1 or mTORC2.  The most well 
studied and understood complex, mTORC1 can be activated through stress, nutrients, 
oxygen levels, and growth factors [80].  Sensing both intracellular and extracellular 
stimuli directly instigates downstream proteins: S6K1 (S6 kinase), 4E-BP1 (eukaryotic 
translation initiation factor 4E-binding protein 1), and SREBP (sterol regulatory element-
binding protein) and autophagy components encouraging  protein synthesis, lysosome 
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biogenesis, and deterring autophagy [81].  Growth signals incorporated through mTOR 
complex 1 sensing energy and nutrient levels encourage proliferation upon promising 
conditions and autophagy upon traumatic conditions [82].   
Tissue damage and repair has be examined through S6K1, a downstream 
regulator, once  activated promotes axon regeneration in a mouse optic nerve crush CNS 
injury model by deleting PTEN (phosphatase and tensin homologue) and TSC1 (tuberous 
sclerosis 1), but not inhibition of 4E-BP [83].  The activation or deactivation of mTORC1 
upon cell or tissue damage invokes molecular signals or biomarkers to initiate adequate 
responses.  For example, enhanced stress resistance and longevity genes were discovered 
in nematode model through inhibition of mTORC1 signaling by regulating SKN-1/Nrf2 
stress transcriptional factor, which is required along with rapamycin [84].   Multiple 
mechanisms are involved in mTOR signaling and mitochondrial function in yeast models, 
demonstrated inhibition on mTORC1 increased chronological lifespan by shifting 
mitochondrial respiration [14]. 
Understanding the inner workings of mTORC2 is not well understood or 
documented as mTORC1.  Mechanisms regarding how stimuli is detected has been 
addressed in yeast and eukaryotes seemed unresponsive to rapamycin (short term 
treatment) and function upstream of Rho GTPases regulating the actin cytoskeleton [85].  
Once activated by ribosomes, mTORC2 solicits help through binding of PI3K, however, 
this mechanism is poorly defined [86].  Several members of AGC (protein kinase A, G 
and C) family of kinases are governed by mTOR complex 2 including Akt, SGK 1( 
serum- and glucocorticoid-induced protein kinase 1) and PKC-α [87].   
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Phosphorylation of AKT at its hydrophobic motif (Serine 473) is required for 
maximal activation of metabolism, cell survival, and apoptosis [88].  Lamming and 
colleagues provided some insight on the role of mTORC2 in three different mouse 
models of RICTOR depletion: heterozygous for RICTOR, RICTOR deleted in the liver, 
and RICTOR induced deletion throughout the mouse model.  Chronic long term 
treatment of rapamycin does effect mTORC1, as well as mTORC2 in vivo, however 
longevity was gender specific, with females outliving their male counterparts [89].   
 
 
 
 Figure 2. Mammalian Target of Rapamycin (mTOR) controls protein synthesis.[90] 
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Interestingly, induction of cytoprotective measures suggests a link between 
mTOR and antioxidant activity, to some degree in some organisms to control a spectrum 
of autoimmune diseases [91, 92], lifespan [35], and mental cognitive abilities [93] [94].  
Pharmacological blockage of mTOR and personalization aimed toward lifespan show 
promise, but not without some adverse events, nonetheless, preventive measures against 
metabolic and neurodegenerative abnormalities provide ideal solutions in the form of 
mTOR inhibitors.   
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CHAPTER III 
EFFICACY OF NANOPARTICLES 
IN AN EX VIVO HUMAN SKIN MODEL OF AGING 
 
III. 1 Introduction  
 
 The skin is the largest and most exposed organ of the body reacts to both natural 
and man-made compounds, making it an ideal model to discern nanoparticle penetration.  
Fullerenes and other substances ability to traverse the skin usually occurs at the stratum 
corneum (Figure 3), outermost layer of the epidermis with a thickness of about 10-40µm 
[95, 96]; this is the rate limiting barrier for absorption of topical formulations [42, 97].  
The route of penetration may occur through hair follicles, sweat ducts, intercellular and 
intracellular corneocyte openings [98, 99].  A thorough understanding of nanoparticles 
penetration process, accumulation in the dermis, and permeability of the stratum corneum 
is not complete and requires more dermal exposure studies to provide a realistic 
representation surrounding skin absorption and nanoparticles [100, 101]. 
 
 
 
                                       Figure 3. Hematoxylin and Eosin (H&E) staining   
                                       representing  the three  layers of human skin.  
                                       Stratum Corneum (SC), Epidermis (E), and Dermis (D).
SC 
E 
D 
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Advancement in nanotechnology have made modifying nanoparticles into 
lipophilic or hydrophilic properties to capitalize on its ability to alter skin morphology. It 
has been well documented that lipophilic molecules less than 600 Daltons (Da) can 
penetrate the skin passively [102], while some have placed maximum size at 400 Da for 
intact skin [103].  Certain areas of the skin allow for nanoparticle penetration, due to the 
lipophilic (stratum corneum) and hydrophilic (epidermis) nature of skin [104]. while, 
others argue due to fullerenes molecular weight (720 Da) prevents skin penetration [105].  
Nanoparticle formulations efficacy on skin can be based on alteration of microscopic 
structures which can be examined by quantitative and qualitative measurements. Souto et 
al [106] reported increased permeation of C₆₀-poly(vinylpyrrolidone) (PVP) upon UVA 
irradiation, indicating human skin being less permeable than porcine skin by means of 
skin diffusion techniques.   
We investigated three nanoformulations (NF) and found remarkable results in 
their ability to provide protection and alter skin architecture.  Each nanoformulation is 
comprised of different functionalized, water soluble fullerenes and efficacy is evaluated 
between different formulations and untreated controls. We used aged human skin as an ex 
vivo model to scientifically document the effects of each nanoformulation alongside 
control, on the basis of skin morphology and histological assessment.  
III. 2 Methods 
 III. 2 .1 Fullerene Preparation 
All fullerene derivatives were obtained from Luna Innovations, Danville, VA.  
Each compound (described previously) [16, 107] was characterized using HPLC, NMR, 
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and MALDI mass spectroscopy. After filtering through 0.22 uM sized membrane filters, 
water solubility was assessed visually using light microscopy and particle sizes were 
analyzed by dynamic light scattering.  
 III. 2 .2 Ex vivo Skin Model    
Human skin was obtained with informed consent from a 35-49 year old females, 
undergoing abdominal or breast reduction from the Cooperative Human Tissue Network. 
All studies were approved by the Human Studies Institutional Review Board. Samples 
had excess fat removed and was placed in RPMI 1640 media (Life Technologies, 
Carlsbad, CA) supplemented with streptavidin and L-glutamine, 10% fetal bovine serum, 
HEPES, and amphotercin B for ~ 1.5 hours.  Afterwards, skin was cut into pieces and 
placed in a 24-well plate with culture medium and incubated at 37°C in 5% CO2.  
Samples were treated with C3
 (C60-tris-malonyl acid), TGA (C70-tetraglycolate), DMAE 
(C60-Dimethylethanolamine) or untreated (control) for two weeks.   
 III. 2 .3 Scanning Electron Microscopy   
Documenting the effects of substances used on skin have been useful to visualize 
alterations in skin surfaces for protein deposits on hair shafts and skin roughness [108]. 
Thus, we used scanning electron microscopy (SEM) on human skin tissue that was 
treated with C3, DMAE and TGA at 1 μg/ml over a two week period. Skin was rinsed 
with 0.1M phosphate buffered saline for 10 minutes and immersed in glutaraldehyde for 
24 hours at room temperature. Skin swatches were washed again to remove excess 
fixation solution. Afterwards, swatches were dehydrated with an increasing gradient of 
acetone at room temperature.  Hexamethylsilane (HMDS) was used to remove excess 
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liquid from the skin sample. Samples were attached to electron microscopy stubs using 
carbon tape and sputter coated with ~10 nm of gold palladium on a Denton Vacuum Inc. 
Desk II Sputter Coater (Denton Vacuum LLC, Moorestown, NJ, USA).  Images were 
captured using a Carl Zeiss Auriga SEM-FIB at magnifications of 47X, 250X and 615X.   
 III. 2 .4 Histology    
Tissues were placed in 70% ethanol and shipped to IHC world (Ellicott City, MD, 
USA) for cutting and staining with Hematoxylin and eosin (H&E)  and Masson-
Trichrome, a three color staining to determine cellular components and epidermal-dermis 
integrity.  Histological procedure was performed in accordance with manufacturer’s 
instructions.  Specimens were visualized using a Zeiss Axio light microscope (Carl Zeiss 
AG, Peabody, MA, USA) for histopathological examination.  Histometric analysis was 
assessed by measuring 150 micrometer width across a 20X H&E image.  Six vertical 
lines were drawn from top of epidermis (minus stratum corneum) to stratum basale to 
transverse across the 150 micrometer width line to collect measurements using Zeiss 
Axio light microscope.   
III. 2 .5 Statistical Analysis 
The data used for histological analysis was analyzed using GraphPad Prism 5.0 
(San Diego, CA) and presented as mean ± SD.  A one-way analysis of variance followed 
by Tukey post test, where p<0.01 was considered significant and highly significant as 
P<0.001. 
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III. 3 Results 
 We used an ex vivo human skin model to assess the skin surface changes induced 
by three nanoformulations.  Control samples (Figure 4A) exhibited some flaking and 
cracking on the stratum corneum, indicative of unhealthy, damaged skin.  Skin samples 
treated with the DMAE, C3, and TGA (Figure 4B, C, and D) displayed minor cracking, 
but less severe compared to untreated naturally aged human skin sample. SEM images of 
skin specimens demonstrated our nanoformulations was more effective at preserving the 
stratum corneum than untreated human skin samples.  
 
 
 
Figure 4.  Nanoformulation creams prevent dermatological destruction associated with 
aging.   Human skin tissue was processed using an ex vivo skin model were treated with various 
              NF (1 μg/ml) over a two week period. Scanning electron microscopy (47X) was used to image 
              samples. Skin pretreatment with A) Control, B) DMAE, C) C3, D) TGA resulted in less flaking  
              of the stratum corneum when compared to control untreated skin. 
 
Skin absorption/penetration was remarkable with the three nanoformulations as 
determined by the quality of the stratum cornuem.  Scanning electron microscopy images 
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from human skin of control, C3, DMAE and TGA groups are presented in Figure 5.  In 
Figure 5A, the image depicts severe damage of untreated skin showing desquamation or 
skin peeling of the tissue at the outermost layer.  Moderate flaking for DMAE (Figure 
5B), C3 (Figure 5C), and TGA (Figure 5D) at higher magnification (250X).  Slight 
peeling on the surface (Figure 5C) revealing pores underneath the stratum corneum can 
be classified as marginal drying of the skin. 
 
 
 
Figure 5. Skin absorption of nanoformulations prevents desquamation. Human skin tissue 
was  processed using an ex vivo skin model were treated with various NF (1 μg/ml) over a two 
week period. Scanning electron microscopy (250X) was used to image samples. Skin 
pretreatment with A) Control, B) DMAE, C) C3, D) TGA resulted in smoother appearance of 
the stratum corneum when compared to untreated skin. 
 
Upon closer SEM examination (615X) definite improvement in skin quality 
proved DMAE and TGA (Figures 6B and 5D) delivered a smoother surface area in 
comparison to control (Figure 6A).  In Figure 6C, C3 did appear to have a slight reduction 
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of desquamation in the outermost layer after two weeks of treatment, confirming some 
beneficial effect over control group but not at levels of DMAE and TGA.  Prominent 
scaling or sheeting seen in Figure 5A (control) measured by the number of raised layers 
on the stratun corneum, indicated quantitatively the efficacy of the nanoformulations.  
Higher magnification for control group (Figure 6A) produced many papule-like structures 
on the epidermis.  Treatment groups DMAE and TGA (Figure 6B and 6D) did not present 
similar structures, but C3
 (Figure 6C) exhibited some characteristics as control group. 
 
 
 
Figure 6. Nanoformulations prevented papular formation. Human skin tissue was treated 
with  various NF (1 μg/ml) over a two week period. Scanning electron microscopy (615X) 
was used to image samples.Skin pretreatment with B) DMAE and D) TGA resulted in 
smoother appearance no papular formation on the stratum corneum when compared to A) 
untreated and C) C3. 
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 To further prove efficacy in an ex vivo human skin model, evaluation of three 
nanoformulations was assessed by hematoxylin and eosin (H&E) staining to determine 
possible tissue pathologies.  The results obtained are presented in Figure 7, which shows 
a transverse section of all groups for characterization of layers and structures of skin 
organization.  Samples treated with nanoformulations (Figures 7B-D) verified SEM 
images (Figures 4-6) and little to no morphological changes in stratum corneum layers 
were detected in comparison to control (Figure 7A).   Histologic analysis revealed tact 
stratum corneum, epidermis, and dermis of DMAE and TGA (Figure 7B and 7D) over 
untreated group (Figure 7A) and C3 (Figure 7C).  
 
 
                      Figure 7. Nanoformulations prevent age-related epidermal detachment. Skin samples 
       treated with and without fullerenes (1 μg/ml) were  placed in 4% paraformaldehyde, mounted,  
       and  stained with Hematoxylin and Eosin (H&E, 10X). The NF prevented the detachment 
       of the epidermal layer compared to non-treated sections.  Groups represented as A) Control,  
       B) DMAE, C) C3, and D) TGA.   
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Microscopically, the human skin model stained with Masson Trichrome revealed 
connective tissue (dark blue), nuclei (red/purple), and cytoplasm (red/pink) as represented 
in Figure 8.  Epidermis and dermis region appeared to be detached from the basement 
membrane in the untreated group (Figure 8A) in comparison to treatment groups (Figure 
8B-D).  In Figure 8B, DMAE produced an intact stratum corneum, epidermis, and dermis 
sections, as well as healthy collagen bundles and epithelial cells.  On the other hand, C3
 
(Figure 8C) showed epidermal-dermis disorganization and separation at the junction.  In 
Figure 8D, TGA caused less epidermal-dermis detachment over control group (Figure 
8A).      
 
 
           
              Figure 8.  Masson Trichrome staining of skin untreated and treated with nanoformulations.  
A) Control, B) DMAE, C) C3, and D) TGA groups treated over a two week period. Skin samples  
processed, mounted, and stained with Masson’s trichrome (10X).  Histological images of collagen    
bundles (dark blue),cytoplasm (red/pink) and nuclei (dark red/purple). 
 
 
All nanoformulations displayed distinct stratified squamous keratinized epithelial 
consisting of keratinocytes, melanocytes and corneocytes in the epidermis layer as well as 
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fibroblasts in the dermis region (Figure 9).  The stratum basale presented a more uniform layer of 
melanocytes and keratinocytes for DMAE (Figure 9B) and fibroblast placement in the dermis 
using higher magnification (20X) as compared to control and other treatments groups (Figure 9C, 
and 9D).  In comparison with control (Figure 9C), C3 presented slight detachment of the 
epidermis-dermis junction but better protection was seen over a two week period in comparison 
to control.  Melanocytes appeared less plentiful at the basement membrane (stratum basale) and 
pale-nuclei of keratinocytes located in the stratum spinosum are more pronounced over control 
(Figure 9A and 9C).  In Figure 9D, stratum basale is heavily populated with resident melanocytes, 
while keratinocytes reside in the upper epidermis layer (stratum spinosum); in addition 
corneocytes (anucleated cells) can be seen in the upper most layer (stratum granulosum) of TGA 
nanoformulation in comparison to control.    
 
 
 
Figure 9. Distinct cell types in the epidermis and dermis layers of skin.  Epidermal-   
dermis junction using Hematoxylin and Eosin (H&E) staining of human skin (20X). 
Stratified squamous keratinized epithelium and connective tissue of the dermis layer 
displayed in A) Control, B) DMAE, C) C3, and D) TGA.   
 
 
Moreover, a diminishing stratum corneum is apparent in all three 
nanoformulations with a complete dissolution in the control group (Figure 10). Densely 
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populated melanocytes and kerationcytes residing in the stratum basale followed by the 
stratum spinosum layer of DMAE, C3, and TGA (Figures 10B-10D) in comparison to 
control group (Figure 10A).  In Figures 10B-10D, all nanoformulations produced normal 
viable cells of the stratum spinosum with well uniform melanocytes and keratinoctyes.  
However, separation of the epidermal-dermis section is seen in C3 (Figure 10C) over 
DMAE and TGA (Figures 10B and 10D) compared to control.  Dermal collagen bundles 
and fibroblast of treatment groups did not show any significant difference to that of 
control. 
 
 
 
     Figure 10. Masson Trichrome staining of epidermal-dermis layers of skin.  
After two weeks of treatments, skin samples were stained with Masson Trichrome (20X).   
Collagen bundles (dark blue), cytoplasm (red-pink) and nuclei (dark/red) can be seen in  
all groups A) Control, B) DMAE, C) C3, and D) TGA.   
 
  
 
A visual difference was detected in the epidermis region of all groups. 
Measurements were taken from stratum lucidum (thin clear layer between stratum 
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corneum and stratum granulosum) to the stratum basale (bottom of epidermis).  
Epidermal thickness was highly significant (p<0.001) for DMAE and TGA while C3 
significantly (p<0.01) increased over control (Figure 11).   
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Figure 11. Measurement of epidermal thickness.  Epidermal 
thickness of human  skin treated with Control, DMAE, C3, and 
  TGA nanoformulations over a two week period, without stratum 
                             corneum. Significance denoted as **p<0.01 and ***p<0.001. 
 
  
III. 4 Conclusions 
 
 To examine the intricacy of skin tissue morphology induced by our 
nanoformulations, histological and scanning electron microscopy techniques provided an 
understanding of skin penetration/absorption with fullerenes.  After two weeks of topical 
treatment, DMAE and TGA maintained an intact epidermis-dermis junction, whereas C3 
and untreated showed signs of disruption.  These finding imply our nanoformulations 
resulted in some protective modifications of the outermost layer of the skin and no 
collagen degradation in the dermis region at a 1µg/ml concentration. 
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 Scanning electron microscopy evaluation of three nanoformulations for their 
ability to topographically alter epidermal skin architecture as shown in Figures 4-6, after 
two weeks of topical treatment.  Microscopy images confirmed treatment groups 
produced a smoother, supple, and healthier surface area over control group, most notably 
DMAE and TGA.  Grossman[109], investigated the safety and efficacy of DMAE 
(dimethylaminoethanol) proving acute skin firming effects measuring quantitatively 
cutaneous tensile strength and improvements (p<0.05) in periorbital fine wrinkles, under 
eye dark circles and neck firmness.   
These findings support our histological analysis (Figures 7B, 8B, 9B, and 10B) of 
fibroblast proliferation in the dermis aiding to increased structural integrity by secreting 
collagen.  Upon microscopic examination, DMAE epidermal thickness and dermal 
density was increased compared to control (Figures 7-10).  The same outcome was seen 
in using DMAE alone and in combination with an  amino acid (AA) compound, once a 
week for 4 weeks of microinjections in rats [110].  According to Proksch et al., skin 
hydration is correlated to integrity of the stratum corneum, indicating good functionality 
of skin mechanism [111].  
 The effects of C3 on skin surface roughness was observed by SEM and histology 
after two weeks of treatment.  Skin flaking can be detected (Figure 6C) but not as severe 
as untreated skin tissue (Figure6A).  Similar results were reported using polymeric 
nanospheres incorporated with water-soluble methylcellulose, for enhanced permeation 
in human cadaver skin after SEM analysis exhibiting some skin flaking [112].  C60 
fullerenes are the most studied nanoparticle due to their ability to scavenge free radicals.  
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What is known about C3 through Dugan et al, is the ability of C3 to act as an superoxide 
dismutase (SOD) mimetic increasing lifespan, reducing free radical production, increased 
mental plasticity in Morris water maze and diminishing age-related immune system 
responses [113, 114].  Interestingly, water-soluble functional groups attached to 
fullerenes reduced cytotoxicity over pristine C60 fullerenes[115].  This suggest C3 
provided some protection against skin surface morphology and cellular function.   
 Microscopic examination of TGA after two weeks of treatment produced an 
increase in epidermal thickness compared to that of control (Figures 9D, 10D and 11). 
This is supported through morphological changes associated with an increased number of 
cells and furrow of the epidermal-dermis junction, indicating proliferating epidermis, 
leading to skin improvement [116]. As previously reported, TGA inhibited cytokine 
production of synovial fibroblast and osteoclast production in an in vivo efficacy study 
[7].  This debunks the notion, TGA provokes inflammatory cells leading to increased 
epidermal thickness.  Upon testing the efficacy of TGA, on an aging skin model, it 
warrants further investigation based on previous research due to its lack of build-up in 
tissue, therefore limiting toxicity[8]. 
 Skin penetration of nanoparticles can be a common strategy for drug delivery to 
transverse intact skin, through weakening highly organized epidermal barrier consisting 
of lipids, stratum corneum, and other epidermal layers [117, 118].  The stratum corneum 
(15µm thick) acts as a barrier to prevent chemicals and particulates from entering the 
body, comprised of anucleated cells (corneocytes) entrenched in a uninterrupted 
intercellular lipid matrix [105].  In Figure 11, a significant difference in epidermal 
 
29 
 
thickness was discovered with all nanoformulations with DMAE and TGA demonstrating 
impressive protection over control. Keratinocytes differentiation, proliferation, and 
cellular death regulates epidermal thickness [119], however, a careful balance must be 
maintained.   
Topical nanoparticles effect on cell morphology and function has come into 
question surrounding viable epidermis ability to change cellular organization.   A study 
conducted by Leite-Silva et al. noted topical application of zinc oxide nanoparticles  on 
the epidermis did not alter metabolic state or morphology of cells in a skin penetration 
study [120].  Although, our nanoformulations differ from Leite-Silva, no cellular 
morphology was detected in this study using topical application in aged human skin.  
Generally speaking, skin penetration of nanoparticles is size, shape, and charge 
dependent as well as mechanical flexion [121, 122].  Additional studies to evaluate 
toxicological effects will need to be conducted to determine safety of these fullerenes in   
human skin.   
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CHAPTER IV 
 
TOXICOLOGICAL ASSESMENT OF NANOFORMULATIONS  
 
 
IV. 1 Introduction 
   
Toxicological evaluations are necessary to understand safety profiles of 
functionalized fullerenes in biological organisms.  Conflicting reports surrounding 
toxicity and inflammatory potential of fullerenes vary based on size[123] , moieties[124], 
and concentration [125, 126]. To address toxic effects of fullerenes a series of 
experiments are needed to estimate genotoxicity, cytotoxicity, dermal and ocular 
irritations corresponding to nanomaterials and biocompatibility.  Most studies have 
focused on short or acute toxicity of fullerenes [127-130] but information on long-term 
human and animal studies are scarce and essential for a thorough risk assessment [42].  
Functionalized fullerenes are attractive nanoparticles due to their cellular 
interactions and solubility in biological systems.   C60 and C70 fullerenes uniqueness 
stems from small size, large surface area, and affinity to react with numerous superoxide 
anions without being destroyed is an advantage as an antioxidant [2].  Radical scavenging 
efficiencies of C60 and C70 fullerenes favor carbon-centered free radicals [131] but 
toxicity of biological function is dependent of chemical moieties attached to the carbon 
cage [44]; allowing up to six electrons to be consumed[2].   
Characterization of chemical toxicities using in vitro cell culture models are 
traditional methods used to screen various concentrations of fullerene derivatives.  
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However, this method, although useful does not fully capture the functionality 
and structural changes associated with ex vivo models of a particular organ system under 
oxidative stress.  Fullerenes have been branded, potent antioxidants, due to their ability to 
scavenge free radicals [5, 132],  protect mouse myoblast cells from oxidative induced 
stress [133], and inhibit organophosphate induced acetylcholinesterase toxicities [134] 
and extend lifespan and rescue age related cognitive impairment in mice [57]. As an 
emerging topic in research, employing fullerenes as novel treatments for cancer, diabetes, 
autoimmune disorders, rheumatoid arthritis, atherosclerosis and hypertension and 
physiological aging can be useful for future therapeutic applications [135, 136]. 
Literature has presented conflicting claims some demonstrating fullerenes as 
potent antioxidants in various cell and tissue types [137, 138], while others have disputed 
this claim [139, 140].  This study is to elucidate functionalized fullerenes mechanism of 
reactive oxygen species generation or elimination, investigated through toxicological 
endpoints.   
IV. 2 Methods 
IV. 2 .1 Fullerene Derivatives  
All fullerene derivatives were obtained from Luna Innovations, Danville, VA.  
Each compound has been described previously [16, 107]. Each was characterized using 
HPLC, NMR, and MALDI mass spectroscopy. After filtering through 0.22 uM sized 
membrane filters, water solubility was assessed visually using light microscopy and 
particle sizes were analyzed by dynamic light scattering.  
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IV. 2 .2 Human Cell and Tissue Culture 
Human skin samples were obtained as noted  above (Chapter 3, Methods) and 
3T3 fibroblasts (ATCC) were maintained at 37°C in a humidified atmosphere with 5% 
CO2, in a HEPES (20mM)–buffered RPMI 1640 cell culture medium (Sigma-Aldrich) 
supplemented with 10% fetal calf serum, 2mM L-glutamine, and 100 IU/ml penicillin 
and streptomycin (Sigma-Aldrich). 
IV. 2 .3 Bacterial Mutagenicity Assay 
 To detect potential fullerene induced gene mutation, Salmonella typhimurium a 
bacterial reverse mutation assay was used to assess DNA damage. Various concentrations 
of fullerenes were mixed with 5 μl of S. typhimurium (TA100) along with reaction 
mixture and grown overnight. Sodium azide was a standard mutagen (positive control) 
and reaction mixture and water (Background) were included in the assay.  Aliquots of 
200 μl of sample material, positive control, and background were added to a 96 well 
plate.  Plates were covered and sealed in an airtight plastic bag and incubated at 37°C for 
three to six days.  Colorimetric analyses of results were based on the number of yellow 
wells (mutated) present in each sample material compared to purple wells (non-mutated).   
IV. 2 .4 Lactate Dehydrogenase (LDH) Cytotoxicity Assay 
To evaluate the release of the enzyme lactate dehydrogenase (LDH) from human 
skin tissue treated with functionalized fullerenes.  Tissues were placed in a 24 well plate 
and media added at the air-liquid interface, exposing only the top layer of the skin 
(stratum corneum). Tissue samples were treated with either DMAE, C3, TGA, or media 
(control) for two weeks.  The release of LDH into tissue culture media was assessed 
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using a commercially available LDH Cytotoxicity Detection Kit (Clontech, Mountian 
View, CA) arding to manufacturer instructions. Experimental controls were as followed: 
Background: tissue culture media and Negative Control: culture media plus tissues.  
Positive Control: tissue treated with 100µM H2O2.  Supernatant (100µl) was removed 
from all groups and plated into a 96-well plate, 100µl LDH assay solution was added to 
each well.  Plates were incubated at room temperature for 30 minutes.   Absorbance was 
measured at 490nm wavelength.  Average of absorbance was calculated for each group in 
triplicate.   
IV. 2 .5 Metabolic Activity Assay (MTT) 
Metabolic activity of 3T3 cells treated with functionalized fullerenes was 
measured using the MTT assay (Invitrogen) based on manufacturer’s instructions.  
Trypan blue was used for cell counting and resulted in 96% viability of untreated cells.  
Cells were plated in a 96 well plate at a density of 1x106 cells/well and treated with 
media (Control), 50µM H2O2. 1µg.ml TGA, or 50µM H2O2/1µg.ml TGA (combination).  
Groups were incubated at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 
hours at 37°C in 5% CO2. After designated incubation timepoints, supernatant was 
removed and rinsed with phosphate buffer saline.  A 10µl of MTT reagent was added to 
all wells and plates incubated at 37°C for 4 hours.  Solution was aspirated from each well 
and 100µl of dimethyl suphoxide (DMSO), resulting in formazan crystals solubizing in 
each well.  Abosrbance intensity was detected by plate reader (BioTek, Winooski, VT) at 
570nm.  All experiments were performed in triplicate.    
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IV. 2 .6 Reactive Oxygen Species (ROS) Measurement 
To measure intracellular production of reactive oxygen species, oxidation-
sensitive fluoroprobe 2′,7′-dichlorofluorescin diacetate (DCFH-DA) fibroblasts were 
exposed to functionalized fullerene at preactivation, 0, 30 and 60 minute timepoints.  All 
parameters were expressed in relative fluorescence units and percent increase or decrease 
in ROS formation compared to control (negative) not treated with H2O2 or TGA.  
Adherent cells was incubated with 100µM carboxy-H2DCF at preactivation, 0, 30, and 60 
minutes.  A working solution was made from a stock prep of DCF, using 100mM DCF-
DA  plus 2.0 ml of loading media (99% basal RPMI 1640 + 1% Fetal Bovine Serum) into 
microcentrifuge tube.  Removal of carboxy-DCF was done by rinsing with PBS and 
adding 1.0 ml PBS containing fullerenes, hydrogen peroxide, or L-ascorbic acid (Sigma-
Aldrich) .to designated test wells.  Fluorescence of DCF at pre activation, 0, 30, 
60minutes was detected by plate reader (BioTek, Winooski, VT) with excitation and 
emission wavelength of 485 and 530nm.   
IV. 2 .7 Phototoxicity Measurement 
Fibroblasts cell were exposed for 30 minutes of light and dark, to measure the 
effects of ultraviolet (UV) radiation on 3T3 cells. Cells were seeded 0.5x106/cells in a 96 
well plate and incubated at 37°C at 6% CO2.  Two plates were used and cells treated with 
media (Control), 100µM L-ascorbic acid (Negative control), 100µM H2O2 (positive 
control), 0.01µg TGA, and 1.0µM TGA.  Plate exposed to lighr was put into UV chamber 
for 30 minutes, while second plate was light protected using aluminum foil.  After 30  
minutes, 100µl of supernatant was aliquoted into another 96 well plate.  A 10µl sample of  
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MTT reagent was added to each well, incubated for 2 hours at 37°C in 6% CO2.  All 
plates were run at 590nm absorbance using a plate reader (BioTek, Winooski, VT) 
measuring colrimetric results. All samples were ran at an n=6 for statistical analysis. 
IV. 2 .8 Statistical Analysis 
The data used for MTT, LDH, ROS formation, and photoxicity experiments were 
analyzed using GraphPad Prism 5.0 (San Diego, CA) and presented a mean ± SD. Data 
was analyzed by one-way ANOVA using Tukey’s or Newman-Keuls multiple 
comparison post hoc test (comparison of more than two groups).   
IV. 3 Results 
Fullerene treatment did not mutate Salmonella typhimurium (TA100) compared to 
positive control sodium azide, a known DNA mutagen used to assess genetic 
modification of unknown chemicals. No mutagenic potential was detected for treatment 
groups at all dose concentrations (1.0, 0.1, and 0.01 µg/ml) treated with either DMAE, 
C3, and TGA after observing test samples through Day 6 (Figure 12).  Statistical analysis 
was conducted using two-way ANOVA, Bonferroni post test to compare sodium azide 
(positive control) to groups over six days.   
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Figure 12. No genotoxic effects of fullerene derivatives using Bacterial  
Mutagenicity Assay. Assay shows the frequency of colonies formed proportional  
               to the mutation frequency induced by fullerenes.  All treatment groups did not  
               show signs of mutagenic potential at dose concentrations (0.01 - 1.0 µg/ml).            
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To test the cytotoxicity of human skin tissue treated with fullerene derivatives, we 
measured LDH levels of tissue culture supernatant after two weeks of exposure.  In 
Figure 13A, analysis indicated that DMAE 1.0µg/ml (p<0.05) and lower concentrations 
(0.01-0.1µg/ml) (p<0.0001) did not produce LDH levels above control.  Results for C3 
(Figure 13B) were split with 1.0 and 0.01µg/ml (p<0.05) indicating little release of LDH, 
but mid concentration 0.1µg/ml (p<0.0001) caused far less LDH leakage in comparison 
to control and both high and low concentrations.  Dose response of TGA (0.01 – 
1.0µg/ml) remained consistent and highly significant (P<0.001) to prevent LDH exposure 
compared to control (Figure 13C).  
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Figure 13. Reduction of Lactate Dehydrogenase enzyme by fullerenes.   
Cytotoxic effects of DMAE, C3, and TGA concentrations (0.001 – 1.0µg.ml)  
suppressed LDH levels after two weeks of treatment.  Results were expressed  
as mean ± SD. *p<0.05, **p<0.001, p<0.0001 comparing LDH release with  
control tissue.   
 
 
 Measurement of the metabolic activity (MTT) of fibroblasts in the presence of 
1.0µg/ml TGA and 1µg/ml TGA/50µM H2O2 produced surprising results (Figure 14).  
TGA alone was found to increase metabolic activity after 30 minutes (p<0.0001) to 2 
hours.  After 2 hours of exposure fibroblasts decreased activity around 4 hours (p<0.05) 
and movement based on absorbance was not detected. Although not significant when 
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compared to control, 12 hour timepoint and beyond did result in increased metabolic 
activity.  In contrast, 1µg/ml TGA in combination with 50µM H2O2 inhibited metabolic 
activity in fibroblasts across all timepoints (p<0.001) in comparison to control.   
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Figure 14. Metabolic activity of TGA increased at high concentration. Fibroblast cells metabolic 
activity measured after treatment with media (Control), 50µM H2O2, 1µg/ml TGA, and 1.0µg TGA/50µM 
H2O2 at the following timepoints: 30 minutes, 60 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 
hours.  Absorbance levels are mean ± SD, *p<0.05, **p<0.001, ***p<0.0001 by one-way ANOVA using 
Tukey post test. 
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The ability of TGA to sequester free radical production is important due their 
ability to cause inflammation leading to tissue damage.  Reactive oxygen species are 
implicated in many oxidative stress related diseases and maintaining a homeostatic 
balance is ideal.  After investigating the role of ROS generation in 3T3 cells after TGA 
exposure, preactivation presented no significance amongst groups (Appendix A).  Percent 
change in ROS formation was calculated from preactivation against all remaining 
timepoints (0 minutes, 30 minutes, and 60 minutes), as represented in Figure 15.   
Initial findings show at zero timepoint 0.01µg and 1.0µg TGA values were lower 
than controls, with 1.0µg TGA exhibiting ROS levels similar to L-ascorbic acid.  
However, upon increased exposure past zero timepoint; ROS formation decreases starting 
at 30 minutes and progressing to 60 minutes, both low and high concentrations of TGA 
decrease ROS production dramatically in fluorescence intensity.  The highest amount of 
ROS formation was 50µM H2O2 (positive control) over all groups. 
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Figure 15. Percent change in ROS production by timepoints.  
Fibroblast cells metabolic activity measured after treatment with media 
(Control), 100µM Vitamin C, 0.01µg TGA, and 1.0µg TGA at the following 
 timpoints: 30 minutes, 60 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and  
24 hours.  Absorbance levels are mean ± SD, **p<0.001, ***p<0.0001 by  
one-way ANOVA using Tukey post test. 
 
To gage the ultraviolet (UV) protection of 0.01 and 1.0 µg.ml TGA 
concentrations on fibroblast cells, we examined it against known photo protectant and 
reactive oxygen intermediate, L-ascorbic acid and hydrogen peroxide, respectively.  Cells 
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were pretreated for 24 hours and samples were rinsed prior to experiment.  Figure 16, a 
low concentration of TGA (0.01- 1.0µg.ml) did not provide photo protection after 30 
minutes (p<0.0001) of exposure reducing metabolic activity.  Surprisingly, TGA at a 
higher concentration (1.0µg.ml) surpassed control and L-ascorbic acid after 30 minutes 
without UV exposure (p<0.0001), but no photo protection was observed after 30 minutes 
of UV exposure.   
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Figure 16. Effects of phototoxicity on fibroblasts treated with TGA.  TGA (0.01 and 1.0µg/ml) 
inhibited metabolic activity after 30 minutes of UV exposure. Pre-incubation did increase metabolic 
activity without UV exposure for TGA 1.0µg/ml after 30 minutes.  Values were expressed as mean ± SD. 
***p<0.0001, comparing metabolic activity with control both in dark and UV exposed. 
 
 
IV. 4 Conclusions 
Safety assessment studies are paramount to understand the role fullerenes play in 
nanotoxicology.  Here we investigated fundamental mechanisms leading to toxicity, such 
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as genotoxicity, cell death, and intracellular reactive oxygen species generation.  
Guidelines issued by the Food and Drug Administration (FDA), Cosmetic, Toiletry and 
Fragrance Association (CTFA) and the Organization for Economic Co-operation and 
Development (OECD) [141] are just a few battery of tests utilized in this study to address 
mechanisms of toxicity in fullerenes.    
Mutagenicity assay, also known as the Ames test, was used to determine optimal 
dose concentrations for a series of fullerenes using Salmonella typhimurium strain as a 
reverse bacteria mutation assay.  Bacterial reverse mutagenicity by functionalized 
fullerenes were examined on TA 100 histidine strain of Salmonella typhimurium; 
generally used to test mutagenicity of compounds due to their sensitive nature toward 
mutants of base pair substitutions. Dose concentrations (1- 0.01 µg/ml) did not show a 
significant increase in the number of bacterial reverse mutation colonies in S. 
typhimurium  (TA 100) strain when compared to negative tests.  As a result, 
functionalized fullerenes were determined not to induce DNA mutation under these 
conditions (Figure 12).   
With regard to genotoxicity, Shinohara et al. examined C60 nanoparticles up to 
1000 micrograms/ml and discovered no genotoxic effects using the Ames test in Chinese 
hamster cells [142].   However, some studies have presented genotoxic effects induced by 
fullerenes implicating oxidative stress, a major mechanism associated with redox 
imbalance between reactive oxygen species and antioxidants [143, 144].   Nonetheless, 
additional experiments will need to be conducted to assess DNA integrity in mammalian 
cell and tissue cultures.   
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Water soluble fullerenes were shown to lack mutagenic potential (Figure 12), but 
long term exposure on the body is of great concern.  Here, we investigated the safety of 
three fullerene derivatuves (DMAE, C3, and TGA) on human skin tissue ability to 
prevent or induce the enzyme lactate dehydrogenase after two weeks of treatment.  The 
present study demonstrated significant dose response reduction of LDH in all three 
fullerene derivatives (Figure 13).  Lactate dehydrogenase release was consistent across all 
concentrations (1.0 – 0.01µg/ml) for TGA in comparison to other groups.  Cytotoxic 
effects of water soluble fullerenes have been well documented for inducing LDH release 
[145] but other studies have proven favorable safety profiles of fullerenes in biological 
systems [7, 43, 146].  Cytotoxicity data in this study supports previous literature findings 
of its ability to inhibit LDH.  An ideal candidate to explore safety assessment and anti-
aging effects was TGA, based on genotoxic and cytotoxic information in this study and 
efficacy studies in the previous section. 
 To establish the metabolic activity of fibroblast cells pre-treated with media, 
50µM H2O2, 1.0µg.ml TGA, and 1.0µg.ml TGA/50µM H2O2 using a MTT assay.  A time 
response study revealed a slow increase in cell growth for 1.0µg.ml TGA (Figure 14).  
The fullerene derivative, TGA, never exceeded cellular growth compared to control, but 
cellular growth was seen within this group (TGA 1.0µg.ml), intermittently.  Initial 
metabolic activity levels of all groups at 30 minutes (p<0.0001) started below control 
group.  But data analysis of 50µM H2O2 (p<0.0001)   and 1.0µg.ml TGA/50µM H2O2 
(combination) (p<0.0001) groups, revealed cellular activity remained below control and 
1.0µg.ml TGA.   A similar effect was seen with pristine C70 fullerenes exposed to human 
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keratinocytes and lung carcinoma cells at various concentrations. Cells exposed at 6 and 
24 hours produced very small changes in cell viability [50].  The present results 
demonstrated TGA alone elicited increase in cellular metabolic activity, while 
combination inhibited metabolic activity in fibroblast cells under these condition. 
Fullerenes have potential to act as potent biological antioxidants, by reacting with 
superoxide anions without being consumed [2].  However, fullerenes and other 
nanoparticles have been associated with toxicities through reactive oxygen species 
production.  Reactive oxygen species induced by nanoparticles are usually followed by 
ROS cell-mediated tissue damage, immune cell activation, and inhibition of cell division 
and cell death [147].  
Previous research of TGA inhibited airway inflammation and caused no acute 
toxicity in liver and kidney tissues in mice [8]. We investigated the inhibitory ability of 
low and high dose TGA concentrations, towards intracellular ROS formation in fibroblast 
cells.  In this study, a time dependent decrease in ROS formation was noticed at high 
concentrations of TGA (Figure 15) in comparison to control.  Percent change in ROS 
formation of control surpassed 1.0µg/ml TGA from 0-60 minutes timepoint.   Inhibition 
of ROS by TGA (1.0µg/ml) produced effects similar to L-ascorbic acid.  L-ascorbic acid, 
a potent water soluble antioxidant is biologically active, but unstable.  This non-
enzymatic defense mechanism helps to overturn ROS in healthy cells.   
Pro-oxidants induced by nanoparticles can exhaust antioxidant reservoirs or 
produce intracellular ROS. Research suggest ROS can be both beneficial and detrimental 
to biological processes.[50, 148].  For example,  PVP-fullerene diminished ROS over 
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ascorbic acid derivative in human skin keratinocytes, suggesting development as a 
rejuvenation cosmetic [149].   Liochev addressed the Free Radical Theory of Aging, 
noting how ROS can be the causative agents of aging but trigger pro survival signals in 
cells to extend lifespan[150].  An example of detrimental effect of ROS proved an 
increase in elastin mRNA levels in dermal fibroblasts, due to ROS imbalance resulted in 
photoaging of skin and inflammation [151].  Therefore, under these conditions TGA has 
potential as an effective inhibitor against ROS formation. 
 Antioxidants can either prevent initiation of free radicals or inactivate free 
radicals and can be depleted upon oxidant induced pathologies.  Enzymatic (catalase and 
superoxide dismutase) and non-enzymatic (vitamin A, C, and E) antioxidants protect 
against photo damage in skin induced by ultraviolet exposure.  Particular attention has 
been towards derivatives of C60 and C70 fullerenes impressive scavenging ability against 
ROS [137, 138, 152].  Our study showed significant (p<0.0001) decrease in metabolic 
activity at TGA (0.01-1.0µg/ml ) after 30 minutes of UV exposure in comparison to 
control (Figure 16).  However, 30 minutes of dark exposure, high concentration of TGA 
(p<0.0001) outperformed ascorbic acid, a known antioxidant used to prevent photoaging 
[151].   
Literature review discovered a similar effect was seen in human lens epithelial 
cells and human retinal pigment epithelial cells using fullerol exposed to UVA resulted in 
a decrease in metabolic activity [145, 153].   Here the cytoprotective effects of TGA was 
unsuccessful in protection against UV exposure (decrease in metabolic activity), leading 
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to tissue damage.  These results indicate a creative strategy to incorporate additional 
ROS-scavenging fullerenes or antioxidant to guard skin from deleterious stimuli.   
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CHAPTER V 
PROTEOMIC EVALUATION ON BIOLOGICAL RESPONSE OF TGA 
 
 
V. 1 Introduction  
 In the previous section, toxicology established TGA suppressed reactive oxygen 
species formation similar to L-ascorbic acid (Figure 15), but photo protection was not 
seen using TGA (Figure 16).  Based on this information, TGA on some level, is 
analogous to an antioxidant’s ability to combat ROS generation.  Cellular toxicity was 
unaffected by TGA, but it does not explain mechanism of aging regarding 
fullerene/protein interactions.   
Proteomics are widely used to interpret post translational modifications of 
fullerene and protein interaction in research.  Interactions such as these, explains aging 
mechanisms at the protein level.  Previous literature has shown the unusual effect 
nanomaterials have on biological systems due to their physicochemical modifications, 
particle size, and charge [154].  Nevertheless, compounded with the assortment of 
negative or positively charged and hydrophilic or hydrophobic nature of proteins; 
fullerenes have become prime targets in aging research.  In one study, negatively charged 
fullerene derivatives induced pro-inflammatory cytokine TNF-α in macrophages, but 
positively charged fullerene derivatives were ineffective [155]. Hydrophobic or 
hydrophilic nature of fullerene derivatives can facilitate cellular effects through 
membrane manipulation [156].   
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Regulation of age and age related pathways manipulated by fullerene interaction, 
incorporates a complex arrangement of altering proteins producing both positive and 
negative outcomes.    For instance, deletion of Rictor in keratinocytes increased lifespan, 
protected from senescence, and stress resistance in mitohormesis [157]; however 
dysregulation of TSC/mTOR contributes to tumor angiogenesis [158].  Our lab has 
reported the inhibitory effect of TGA on aging related disorder, inflammatory arthritis, 
suggesting it as a therapy against arthritis [7].  This study can provide insight into 
fullerene’s ability to modulate protein expression along the mTOR pathway and its 
mediators.   
V. 2 Methods 
 
V. 2 .1 Fullerene Derivatives 
  TGA was purchased from Luna Innovations Incorporated (Danville, Va) [8, 9].  
Characterization was done using matrix assisted laser desorption ionization mass 
spectrometry, nuclear magnetic resonance, and high performance liquid chromatography 
[44].  Z-average (mean value of the hydrodynamic diameter) of ~111.2 nm C70-TGA 
(1μg/μl) in sterile water and the zeta potential was obtained by Nano-ZS Zetasizer 
NanoSeries with DTS software (Malvern Instruments, Zetasizer, NanoZS, Westborough, 
MA).  
V. 2 .2 Cell Stress Protein Array 
The expression profile of cell stress related proteins induced by two different 
fullerene derivatives (FD), C3 and TGA.  A protein array was performed using the 
Proteome Profiler Antibody Array kit (R&D Systems, Minneapolis, MN, USA) 
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according to manufacturer’s instructions.  Skin samples were treated with either C3, TGA 
or untreated (control) for two weeks. Protein quantification was performed using a 
Bradford Assay and 300 μg proteins from each sample were incubated with the cell stress 
protein array overnight at 4°C.  Cell stress membranes were quantified and image 
analysis by Bio Rad ChemiDoc (Bio Rad, Hercules, CA, USA) according to 
manufacturer’s instructions. 
V. 2 .3 Ex vivo Skin Model Treated with TGA and H2O2-mediated Activation  
Human skin was obtained with informed consent from a 55 year old female, 
undergoing breast reduction from the Cooperative Human Tissue Network and approved 
by their Human Studies Institutional Review Board. Samples had excess fat removed and 
was placed in RPMI 1640 media (Life Technologies, Carlsbad, CA) supplemented with 
streptavidin and L-glutamine, 10% fetal bovine serum, HEPES, and amphotercin B for ~ 
1.5 hours. Ex vivo human skin treated with TGA and activated with H2O2 (Figure 1), was 
placed in RPMI media and incubated at 37°C in 5% CO2. 
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The next day, skin samples were washed three times in phosphate buffered saline 
and immediately submerged into liquid nitrogen.  All skin samples were placed in -80°C 
until further analysis. The dosage of 50 µM H2O2 was ideal for oxidative stress activation 
based on literature search [159].  Tissue samples were used for microarray and western 
blot analysis to determine TGA effect on protein modification. 
V. 2 .4 Tissue Lysate Preparation and Antibody Protein Array  
Skin tissue was rinsed three times with PBS then ~250mg of tissue was cut from 
sample.   Tissue samples were homogenized on wet ice using a Bio-Gen Pro200 
homogenzier (Pro Scientific, Oxford, CT).  Samples were sonicated four times for 10 
seconds in ice to shear nuclear DNA using a Beckman Microfuge R centrifuge (Beckman 
Coulter, Inc., Pasadena, CA).  Supernatant was transferred to a new tube and protein was 
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quantified using Bradford assay (Bio Rad, Hercules, CA).  All tissue lysates were placed 
immediately in -80⁰C for further analysis by Kinexus™ Antibody Microarray Service. 
Proteins potentially regulated in skin under the conditions above were 
investigated using a KAM-880 protein microarray as we have performed previously 
[160] (Kinexus Bioinformatics Corporation, Vancouver, BC), 50 µg of tissue lysate from 
each sample was covalently labeled with a fluorescent dye (Kinexus Bioinformatics 
proprietary methodology).  Free dye molecules were removed by gel filtration, followed 
by blocking of non-specific sites on the array.  Two samples (control and treated) are 
loaded on the sample chip in duplicate and incubated (details available at 
www.kinexus.ca).  The Kinexus™ protein array profile was used to detect over 800 
different antibodies. Unbound dye-labeled proteins were washed away and protein 
captured using a 16-bit laser array scanner (Perkin Elmer ScanArray Reader, Waltham, 
MA).  Signal quantification measured using ImaGene 9.0 (BioDiscovery, El Sequndo, 
CA) and results were reported in Z scores (±1.2 – 1.5, significant), percent change from 
control (%CFC) and percent range in error and fold changes using globally normalized 
data as expressed spot intensity between control and treatment samples. 
V. 2 .5 Protein Extraction and Western Blot Analysis 
Skin samples were removed from -80⁰C and ~0.1g – 0.2g frozen tissue was added 
to a 2ml microcentrifuge tube containing 1ml of RIPA Buffer (Boston BioProducts, 
Ashland, MA) and 10μl of protease inhibitor (Sigma-Aldrich, St. Louis, MO).  Samples 
were homogenized using a Bio-Gen Pro200 homogenzier (Pro Scientific, Oxford, CT) on 
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ice. Samples were centrifuged at 16,000 g for 25 minutes and protein concentration 
determined using Bradford protein assay (BioRad, Hercules, CA). 
For validation, 100 µg of protein derived from human skin was subjected to 
Western blot analysis.  Samples were mixed with reducing buffer (0.125M Tris-HCl pH 
6.8, 4% sodium dodecyl sulfate, 0.02% bromophenol blue, 10% β-mercapethanol, 20% 
glyercol) and heated to 95⁰C for 5 minutes. Protein lysate were run in duplicate on 4-20% 
gradient SDS-PAGE gel (Invitrogen, Carlsbad, CA) and transferred onto a nitrocellulose 
membrane (Invitrogen, Carlsbad, CA).  Membranes were blocked with LiCor blocking 
buffer (PBS) (Lincoln, NE) for 1 hour at room temperature, then probed with primary 
antibodies mTOR, RAPTOR, RICTOR (Cell Signaling, Danver, MA) diluted with 0.2% 
Tween 20  and LiCor blocking buffer for overnight incubation.  Membrane was washed 
twice for ~10 minutes in PBST, and then probed using a secondary antibody label using 
an IR-Dye 670 or 800cw goat anti-rabbit or anti-mouse antibody mixed with 0.2% Tween 
20 and blocking buffer for 1 hour at room temperature.  Secondary antibodies were 
washed twice at 10 minutes, and then placed in PBS.  Membranes were imaged wet using 
an Odyssey Imaging system (Lincoln, NE).  Band intensity was measured by placing a 
box around bands and using the raw intensity values to quantify protein expression. β-
actin (Sigma Aldrich, St. Louis, MO)was used as a background subtraction to determine 
protein expression levels.   
Protein samples were imaged using chemiluminescent (ECL) and GE Amersham 
Imager 600 (Marlborough, MA).  All protein extraction and preparation was same as 
above.  Membranes were blocked with 5% nonfat dry milk and Tris-buffered saline 
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(TTBS) for 1 hour at room temperature, rinsed three times with TTBS, then probed with 
primary antibodies phospo mTOR, RAPTOR, RICTOR, SOD2, ATG13,pATG13 (Cell 
Signaling, Danver, MA) for overnight incubation.  Membrane was washed three times for 
~10 minutes in TTBS, and then probed using a secondary antibody label using anti-rabbit 
or anti-mouse antibody mixed with TTBS and 5% fetal bovine serum for 1 hour at room 
temperature.  Secondary antibodies were washed three times at 10 minutes, and then 
placed in TTBS.  Membranes were imaged using an Amersham Imaging 600 system 
(Marlborough, MA). 
V. 2 .6 Statistical Analysis 
The data used for these experiments DLS, ζ-potential, and western blot analysis 
was analyzed using GraphPad Prism 5.0 (San Diego, CA) and presented a mean ± SD. 
Data was analyzed by unpaired two-tailed t-test (comparison of two groups) or one-way 
ANOVA using Tukey’s multiple comparison post hoc test (comparison of more than two 
groups).  Significance was reported as a P-value < 0.05. 
V. 3 Results 
  
 A cell stress protein array was used to detect 26 proteins associated with cellular 
stress. Tissue samples were treated for two weeks with C3, TGA, or media (control).  
Superoxide dismutase 2 (SOD2), plays an important role in antioxidant defense against 
superoxide anion (O2-), in relation to, oxidative stress. As shown in Figure 17, C3 and 
TGA decreased the expression of SOD 2 (p<0.0001) and thioredoxin 1 (p<0.05) by C3 
only, suggesting that proteins were under less duress. However, due to inconsistencies 
regarding protein arrays, western blot validation is necessary.   
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Figure 18. Fullerene Derivatives prevent upregulation of age-associated cell stress proteins. Human 
skin  tissue was treated with or without fullerenes (0.01 μg/ml) and total protein extracted after two weeks. 
The protein extracts were examined for relative protein expression of 26 cell stress related proteins using a 
protein array (R&D Systems). Fullerene-treated skin samples significantly inhibited the upregulation of 
SOD2 and Thioredoxin 1. Mean ± SD taken in duplicates.  * p<0.05, # p<0.0001.   
  
To investigate the effects of TGA on oxidative stress-induced in human skin 
tissue was incubated with or without H2O2 following pre-incubation with TGA.  The 
Kinexus™ protein microarray probed over 100 proteins including phosphorylated sites 
using 50µg of protein lysate. Approximately, 71 proteins were inhibited by 10% or more 
when tissue was pre-treated with TGA and activated with 50µM H2O2. , in comparison to 
untreated based on percent change from control (%CFC) data (Appendix A, Table 2).   
Many of these proteins are linked to mTOR, a serine/threonine kinase, responsible for 
many health, disease, and aging related processes [161].   However, pre-incubation of 
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TGA prior to H2O2 challenge prevented the upregulation of several mTOR-related 
proteins. For example, S6K (ribosomal protein S6 kinase), a downstream effector, 
impaired adipocyte generation in mice fed a high fat diet (HFD)-induced obesity [162] as 
seen in Figure 19.  
   
 
 Figure 19. Inhibition of proteins associated with mTOR pathway treated with TGA and/or 50µM 
H2O2. Expression levels of Akt (PKBa-Y474), S6K, 4E-BP1 (S65), p70 S6K, PRAS40, and p70 S6K 
(S411).  Kinexus protein microarray analysis using 50µg protein lysate to probe protein expression.  
Results expressed as relative protein expression levels using percent change from control (%CFC).  Tissue 
lysate measured in duplicate.  Tissues were pretreated with or without 1 µg.ml TGA overnight at 37°C/6% 
CO2. The next day tissues were washed and challenged with (+) or without (-) hydrogen peroxide (50 µM) 
for 24 hours.  Tissue lysate was used for protein isolation and protein microarray as described above or for 
Western blotting.  Each condition was performed in quadruplicate. Shown is the mean relative intensities of 
each protein (±SD of four observed values) normalized against control.  The black bar is the percent change 
in TGA treated tissues compared to hydrogen peroxide (white bar) treated tissues.  The gray bar is the 
percent inhibition comparing FD pretreated and challenged tissues compared to non-FD treated hydrogen 
peroxide tissues.       
 
An increase in total mTOR (43.74%) and pmTOR (S2448) (1.64%) for 
combination was seen over control levels (Figure 20) in samples treated over a three day 
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period.  A few downstream effectors associated with the mTOR pathway were 
upregulated after pretreatment with TGA and activated with H2O2.  In Figure 21, 4E-BP1 
(2.28%), eIF4B (2.35%) and 4E-BP1 (T45) (6.53%) showed increased levels in skin 
tissue.  These are a few proteins known as direct downstream effectors functioning as 
adaptor protein , protein kinase, or translation inhibitor along the mTOR pathway[163] 
[164]. Validation of key microarray protein results were conducted by western blot as an 
alternative approach to reduce false positives or negatives. 
 
 
 
Figure 20. Inhibition of proteins associated with mTOR pathway treated with TGA and/or 50µM 
H2O2.Expression levels of p70 S6K (T421/S424), ATF2 (T69/T71), S6, p70 S6k (S424), AKT1 (PKBa) 
and S473 (eIFG (S1108).  Kinexus protein microarray analysis using 50µg protein lysate to probe protein 
expression.  Results expressed as relative protein expression levels using percent change from control 
(%CFC).  Tissue lysate measured in duplicate. Tissues were pretreated with or without 1 µg.ml TGA 
overnight at 37°C/6% CO2. The next day tissues were washed and challenged with (+) or without (-) 
hydrogen peroxide (50 µM) for 24 hours.  Tissue lysate was used for protein isolation and protein 
microarray as described above or for Western blotting.  Each condition was performed in quadruplicate.  
Shown is the mean relative intensities of each protein (±SD of four observed values) normalized against 
control.  The black bar is the percent change in TGA treated tissues compared to hydrogen peroxide (white 
bar) treated tissues.  The gray bar is the percent inhibition comparing FD pretreated and challenged tissues 
compared to non-FD treated hydrogen peroxide tissues.  
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Figure 21. Inhibition of proteins associated with mTOR pathway treated with TGA and/or 50µM 
H2O2.Expression levels of IRS (Y612), AKT1 (PKBa) Y326, AKT2 (PKBb), eIF4E (S209), IRS1 (S639), 
and PTEN.  Kinexus protein microarray analysis using 50µg protein lysate to probe protein expression.  
Results expressed as relative protein expression levels using percent change from control (%CFC).  Tissue 
lysate measured in duplicate. Tissues were pretreated with or without 1 µg.ml TGA overnight at 37°C/6% 
CO2. The next day tissues were washed and challenged with (+) or without (-) hydrogen peroxide (50 µM) 
for 24 hours.  Tissue lysate was used for protein isolation and protein microarray as described above or for 
Western blotting.  Each condition was performed in quadruplicate.  Shown is the mean relative intensities 
of each protein (±SD of four observed values) normalized against control.  The black bar is the percent 
change in TGA treated tissues compared to hydrogen peroxide (white bar) treated tissues.  The gray bar is 
the percent inhibition comparing FD pretreated and challenged tissues compared to non-FD treated 
hydrogen peroxide tissues.       
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Figure 22. Down and upregulation of proteins associated with mTOR pathway treated with TGA 
and/or50µM H2O2.  Expression levels of PTEN (S380/T382/T383), pmTOR. 4E-BP1, eIF4B (S422), IRS1 
(S312), eIF4E, Akt1 (PKBa), 4E-BP1 (T45), PI3- Kinase, p70 S6K (T229), eIF2e (S52), and mTOR.  
Kinexus protein microarray analysis using 50µg protein lysate to probe protein expression. Results 
expressed as relative protein expression levels using percent change from control (%CFC). Tissues were 
pretreated with or without 1 µg.ml TGA overnight at 37°C/6% CO2 . The next day tissues were washed and 
challenged with (+) or without (-) hydrogen peroxide (50 µM) for 24 hours.  Tissue lysate was used for 
protein isolation and protein microarray as described above or for Western blotting.  Each condition was 
performed in quadruplicate.  Shown is the mean relative intensities of each protein (±SD of four observed 
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values) normalized against control. The black bar is the percent change in TGA treated tissues compared to 
hydrogen peroxide (white bar) treated tissues.  The gray bar is the percent inhibition comparing FD 
pretreated and challenged tissues compared to non-FD treated hydrogen peroxide tissues.  
      
 
 
 
Figure 23. Upregulation of proteins associated with mTOR pathway treated with TGA and/or 50µM 
H2O2. Expression levels of eIF4G (S1232) and eIF2a.  Kinexus protein microarray analysis using 50µg 
protein lysate to probe protein expression.  Results expressed as relative protein expression levels using 
percent change from control (%CFC).  Tissue lysate measured in duplicate.  Tissues were pretreated with 
or without 1 µg.ml TGA overnight at 37°C/6% CO2.  The next day tissues were washed and challenged 
with (+) or without (-) hydrogen peroxide (50 µM) for 24 hours.  Tissue lysate was used for protein 
isolation and protein microarray as described above or for Western blotting.  Each condition was performed 
in quadruplicate. Shown is the mean relative intensities of each protein (±SD of four observed values) 
normalized against control. The black bar is the percent change in TGA treated tissues compared to 
hydrogen peroxide (white bar) treated tissues.  The gray bar is the percent inhibition comparing FD 
pretreated and challenged tissues compared to non-FD treated hydrogen peroxide tissues.       
  
Western blot analysis of tissue lysate was conducted to confirm the microarray 
data examining expression used in the protein array (Figures 19-23). mTOR protein 
levels did not show significant inhibition in either TGA or TGA-H2O2-challenged tissue 
samples compared control (Figure 24). This is a difference in protein microarray data of 
the previous section.  Raptor (an mTOR-binding protein) was significantly inhibited 
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(p<0.0001) when treated with TGA or TGA-H2O2-challenged treated cells over control 
group.  
 
 
 
Figure 24. Western Blot analysis of mTOR and Raptor. A) Western blot analysis for validation of 
mTOR and Raptor protein levels.  B) Quantification of mTOR and Raptor protein levels treated with 50 
μM H202 or 1 μg/ml TGA on human skin samples. Protein results represent the average protein expression 
and SEM of mTOR and Raptor, *** (p<0.001) highly significant changes in expression levels comparing 
all treatment groups to control.   
 
 
 Western blots were conducted using chemiluminescent due to equipment change 
during experimentation. In light of the role mTOR plays in aged skin, we investigated 
proteins associated with the mTOR complex.  Protein expression was seen for mTOR in 
both TGA and TGA challenged with H2O2 (no significance); however, a down regulation 
was seen for RICTOR and RAPTOR (TGA, p<0.05 and TGA/H2O2, p<0.01) in 
comparison to control in Figure 25.  ATG13 was downregulated in all treatment groups 
(p<0.001).  Some slight differences was seen between protein microarray data and 
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western blot analysis.  For example, pmTOR (S2448) microarray TGA was down 
regulated (-2.57%) but visually western blot presented a slight increase in change from 
control.  A complete contradiction in analysis between microarray and western blot 
demonstrated a downregulation for both TGA and H2O2-challenged TGA for total mTOR 
(Figures 24 and 26), but upregulation in microarray(Figure 22).   
 
 
 
Figure 25. Western Blot analysis of proteins associated with the mTOR pathway.  Results of western 
blot analysis of pMTOR (S2448), ATG13, SOD2, RICTOR, RAPTOR, and β-actin in human skin. Samples 
were treated on Day 1 with media (Lane 1), 50µM H2O2 (Lane 2), or TGA (Lane 3 and 4).  Day 2-50µM 
H2O2 added to Lane 4. Day 3 all samples were removed for protein extraction. Lanes are represented as 
followed: Lane 1: Media only (control), Lane 2: 50µM H2O2, Lane 3: TGA, Lane 4: TGA and 50µM H2O2. 
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Figure 26.  Densitometry of proteins associated with the mTOR pathway.  Results of western blot 
analysis of pMTOR (S2448), ATG13, SOD2, RICTOR, RAPTOR, and β-actin in human skin. Samples 
were treated on Day 1 with media (Lane 1), 50µM H2O2 (Lane 2), or TGA (Lane 3 and 4).  Day 2-50µM 
H2O2 added to Lane 4. Day 3 all samples were removed for protein extraction. Lanes are represented as 
followed: Lane 1: Media only (control), Lane 2: 50µM H2O2, Lane 3: TGA, Lane 4: TGA and 50µM H2O2. 
 
 
Skin tissue was exposed to a pro-oxidant (50µM H2O2) to determine protein 
expression levels for superoxide dismutase 2.  Densitometry was performed on 
chemiluminesence, due to fluorescence measurement unavailability.  Previously, in 
Figure 18, a lower concentration of TGA (0.01µg) reduced SOD2 expression (p<0.0001) 
in human skin.  Upon further investigation, TGA (1.0µg) lowered SOD2 protein 
expression (no significant), but H2O2-challenged TGA showed significance (p<0.05) over 
control in reducing antioxidant defense protein, SOD2 (Figure 27).   
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Figure 27.  Inhibition of Superoxide Dismutase by TGA in Human Skin. Skin samples were treated 
over three days with either TGA, TGA and activated with 50µM H2O2, or untreated (Control) in a 24 well 
plate.  Protein lysate was extracted and loaded into a 4-20% Tris-glycine gel. Protein expression levels of 
SOD2 inhibited by TGA in tissue, similar to expression seen in cells. Results depicted as mean ± SD, 
*p<0.05. 
 
 
V. 4 Conclusion 
 
In Figure 17, inhibition of cellular stress in protein lysate of human skin treated 
with C3 or TGA in comparison to control.  Previous results from toxicology assessment 
correlate with the lack of ROS generation, which support these findings at a protein level 
through the reduction of cellular antioxidants induced by fullerene derivatives.  A 
significant attenuation of SOD2 (p<0.0001) by both TGA and C3; while Thioredoxin 1 
showed significance (p<0.05) for C3, no expression was detected for TGA as a means to 
perform as a cellular defense mechanism.  
Thus, we hypothesized that TGA could counteract oxidative stress-induced 
damage to human skin. For instance, previously we examined the effects of fullerene 
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derivatives on aged skin and discovered a thinning epidermis and induction of cellular 
stress response in SOD2 as well as ROS formation in control, while fullerene derivatives 
demonstrated an opposite effect. This and a previous study [165] has established these 
factors essential for understanding the aging process.   These mechanisms are in place to 
alleviate deleterious effects of reactive oxygen species via enzymatic and/or non-
enzymatic antioxidants.  Previous studies have investigated SOD2 and mitochondria 
function related to aging and have shown that tris-malonic acid derivative of the fullerene 
C60 molecule (C3) acts as a SOD2 mimic in Sod2
−/− mice, which lack expression of 
mitochondrial manganese superoxide dismutase (MnSOD), increased their life span by 
300% [4].  Nano-Pt has been shown to prolong worm lifespan in a dose-dependent 
removal of superoxide anion and hydrogen peroxide by resembling SOD2/catalase 
biologically [166].   
Thioredoxin 1 expression is found in all mammalian cells and tissues, located in 
the nucleus, plasma membrane and protein secretion.  To reduce ROS damage caused by 
mitochondrial respiration, thioredoxin 1 is utilized by mitochondrion and the nucleus 
requires the presence of reduced thioredoxin for transcription factor activation. Cytosolic 
thioredoxin controls cellular growth, apoptosis and inflammation.  In the cytoplasmic 
regions of the cell is a regulator of cell signaling, stress, and transcription factors [167-
170]. A study conducted by Young, et al., found suppression of thioredoxin 1 in human 
fibroblasts induced premature senescence by upregulating p53/p21 (Cip/Waf1) and p16 
tumor suppressor pathways, in turn may enhance organismal longevity [171] because 
these pathways are believed to promote organism aging [172]. 
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We have previously reported that fullerenes can counteract the effects of various 
ROS inducers including H2O2 [4, 8, 44] and reduce inflammatory mediator release from 
skin mast cells [44].  Upstream effectors of mTOR/Raptor complex such as: AKT, PI3K, 
and MAPK as well as downstream effectors S6 (S235/236), S6K1, and/or 4E-BP1/EIF4E 
are ideal targets for mitigating cellular aging [67].   Upregulation of mTOR by these 
effectors can lead to senescence and aging at both the cellular and organismal level.  
mTOR-related proteins that were significantly inhibited by TGA include Raptor (Figures 
24 - 26).  Our results in this study, follow a similar response in TGA treated samples 
effect on mTOR on aged skin.  Lucafo and colleagues, reported fullerene treated MCF7 
cells inhibited mTOR signaling through investigation of gene expression profiles [61].  
These observations were similar with our lab experiments, and may suggest TGA may 
directly or indirectly influence the mammalian target of rapamycin (mTOR) pathway. 
The current study suggests Raptor’s role as a scaffolding protein connecting 
mTOR and phosphorylating substrates for mTOR activation [173].  The quantitative 
analysis of mTOR substrate signaling, only confirms translational levels, additional in-
depth experiments to understand TGA interaction with the mTOR-Raptor complex are 
necessary to address the underlying molecular mechanisms. The selective mTOR 
inhibitor, rapamycin has been used as a positive control, to attenuate pathological defects 
in Alzheimer’s mouse studies [174], while C60 fullerenes [43],  and single walled carbon 
nanotubes [175]  have been shown to inhibit mTOR activation.  Little research has been 
conducted investigating the mTOR-Raptor complex and the effects of C70 to alter this 
pathway.  Therefore, we can only conclude from previous studies focusing on the mTOR-
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Raptor interaction, that show consistency with other mTOR inhibitor studies [176-178], 
to conclude that dissociation of Raptor from mTOR suppresses mTOR expression via 
TGA administration, thereby potentially suppressing cellular aging.  
Potential target proteins were exposed using a Kinexus microarray to elucidate 
unknown mechanisms of aged skin treated with TGA or H2O2-challenged TGA.  Another 
substrate of mTOR is S6, ribosomal protein S6 and 4E-BP1, plays a major role in cell 
proliferation, growth, and survival [179].  4E-BP1 has several phosphorylation sites 
Thr46, Ser65, Thr70, Ser112, Sear 101, and Thr37[179, 180]; where Ser65 is more 
sensitive than Thr46[181].  These phospho sites are necessary for binding or dissociation 
of 4E-BP1-eIF4E complex. A dephosphorylation of 4E-BP1 and increase in eIF4E is 
correlated with environmental stress or infection [181, 182]. In this study, 4E-BP1 (S65) 
and (Thr46) was downregulated by TGA, whereas H2O2-challenged TGA upregulated 
4E-BP1 (Thr46) and downregulated Ser65.  A similar event was reported by Gingras et 
al., where Thr 46 was relatively insensitive to serum deprivation and rapamycin 
treatment,  thereby blocking translation factor, eIF4E [181].   
Activation of mTOR/S6/4E-BP1 leads to initiation of translation and cell growth, 
cellular senescence and aging[183]. Blocking of eIF4E and eIF4E (S209) was seen across 
both TGA and H2O2-challenged TGA (Appendix A, Table 2.), indicating even partial 
inhibition can impede eIF4E binding to 4E-BP1. Microarray data for S6 (Appendix A, 
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Table 2) produced a reduction in protein expression along with western blot analysis for 
mTOR/Raptor complex (Figure 24) suggesting a decrease in the aging process.   
In contrast, others have argued the suppression of SOD2, inhibition of mTOR 
axis, and induction of autophagy have contributed to senescence, leading to accelerated 
aging [184].  Basal levels of cellular degradation (autophagy) are common to maintain 
cellular homeostasis, but accelerated levels are usually seen with enhanced ROS levels 
[185].  In the current study, ATG13, mTOR, and SOD2 levels were all diminished for 
both TGA and H2O2-challenged TGA (Figures 25, 25 and 27).  It should be noted that 
autophagy is a cytoprotective process, not a destructive one. The role of mTOR and 
autophagy has been establish through various organisms[186, 187]  Inhibition of mTOR 
triggers dephosphorylation of ATG13 allowing the formation of ATG13-ATG1 complex, 
but activation of mTOR phosphorylate ATG!3 preventing ATG1-ATG13 formation 
[185].  A few pieces of the puzzle is missing with this study and that is pATG13.  This 
key component will verify whether TGA or combination can activate pmTOR to 
phosphorylate this protein preventing ATG13-ATG1 formation leading to autophagic 
initiation [185].   
 mTOR is a negative regulator of autophagy and inhibition under starvation 
conditions leads to induction of autophagy by means of activating 
mTOR/ATG13/ULK1/ULK2 [188].  A key component to longevity is caloric restriction, 
which can induce autophagy through inhibition of IGF (Insulin growth factors) and 
mTOR target [189].  In contrast, several researchers have noted that lifespan cannot be 
extended with caloric restriction if mTOR is suppressed as reported in worms, flies, and 
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yeast [189, 190]. Furthermore, inhibition of mTOR-Raptor (mTORC1) on protein 
translation was examined via S6K/4E-BP1/EIF4 complex where inhibition of S6k 
extended lifespan in mammals [191].  Although, an increase in autophagy was not seen in 
this study, it should be noted, normal levels of autophagy could suffice for removal of 
dysfunctional proteins if optimal numbers are maintained [188]. 
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Figure 28. Relative Intensity of ROS generation using DCF assay. DCF analysis of 
intracellular generation of free radicals in response to C70-TGA.  ROS generation was not seen a 
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0.01 or1 µg TGA for all timepoints measured when compared to control.  No significance was 
seen acrossall treamment groups. Experiment was conducted in triplicate and mean ± SD 
represented in graph. 
 
 
Table 2. List of Proteins affected by TGA and/or 50 μM H2O2. 
 
Target Protein Phospho-site %CFC                
50µM 
H2O2 
%CFC            
1µg/ml 
TGA 
%CFC                
50µM 
H2O2/1µg/ml 
TGA  
MEK2 mouse T394 -30.70 -55.00 -66.23 
IRS1 Y1179 -61.27 -33.90 -59.93 
IR Y972 -21.85 -7.93 -53.38 
p38d MAPK Y182 -9.99 -7.84 -52.65 
ACTA1 (Alpha -
actin) 
Pan-specific -35.31 -16.02 -52.01 
p53 S392 -25.14 -5.04 -51.25 
MEK2 human T394 -34.93 -3.06 -50.71 
p53 Pan-specific -10.59 2.05 -50.69 
MEKK1 Pan-specific -37.88 -38.02 -50.14 
Akt1 (PKBa) Y474 -32.09 -11.64 -47.40 
S6K T412 -32.62 -22.07 -47.30 
4E-BP1 S65 -45.84 -22.00 -47.03 
p38b MAPK T180+pY182 -16.28 -16.24 -46.36 
p70 S6K Pan-specific -24.63 -12.09 -45.52 
MEK1 S298 -41.64 -37.63 -44.65 
PRAS40 T246 -17.87 -23.68 -44.43 
MEK4 S257/T261 -9.47 -11.15 -41.18 
MEK2 T394 -26.89 -7.64 -40.53 
STAT3 Y704 -14.53 -15.08 -39.93 
Abl Y393 -24.16 -19.31 -39.09 
MEK7 Pan-specific -24.65 7.50 -38.51 
Abl Pan-specific -8.50 -6.58 -37.68 
MEK3b Pan-specific -10.44 -20.88 -35.90 
MEK1 S292 -36.91 -8.61 -33.57 
MKK3 S218 -3.10 -12.05 -33.17 
JNK3 Pan-specific -10.61 -12.64 -33.04 
STAT5A S780 -30.11 -5.19 -32.45 
p70 S6K S411 -15.98 4.78 -32.30 
PTEN S380/S382/S385 -33.53 -27.63 -31.80 
MKK3 S189 -28.06 -3.47 -31.31 
Vimentin S33 -32.43 -10.49 -30.99 
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p70 S6K T421/S424 -38.63 -5.19 -30.07 
ATF2 T69+T71 -32.26 -20.55 -29.43 
S6 S235 -38.23 -17.96 -27.70 
Fos T232 -14.74 9.54 -27.35 
IKKa Pan-specific -0.65 -18.46 -26.21 
*List of C70-TGA and/or 50 μM H2O2 affected antibody microarray results (duplicate spots).  
Site of phosphorylation is given after protein name.  %CFC, percent change from control. 
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Table 2. List of Proteins affected by TGA and/or 50 μM H2O2. (Cont’d) 
 
Target Protein Phospho-site %CFC                
50µM H2O2 
%CFC            
1µg/ml TGA 
%CFC   
50µM 
H2O2/1µg/ml 
TGA 
ASK1 S966 -17.00 -31.33 -25.33 
IKKa T23 0.34 1.01 -23.53 
ERK1/2 T202+T185 -29.78 -19.22 -23.42 
p70 S6K S424 -10.76 35.21 -23.39 
Jun S73 -29.92 -17.29 -23.35 
CDK1 Y19 -13.50 -4.97 -21.65 
Hsc70 Pan-specific -23.52 52.54 -21.30 
MAPKAPK2 Pan-specific -42.32 -18.68 -21.14 
MEK3/6 S189 + S207 -34.36 -14.07 -20.20 
SOD (Cu/Zn) Pan-specific -21.14 0.47 -19.93 
DUSP10 Pan-specific 5.89 -7.12 -19.42 
Cyclin D1 Pan-specific 22.37 3.43 -18.28 
Akt1 (PKBa) S473 -16.52 1.26 -18.16 
p53 S6 -4.50 18.48 -16.95 
Jun Pan-specific -24.50 -13.51 -16.37 
eIF4G S1108 -22.39 1.40 -16.20 
p38a (MAPK 14) Pan-specific -12.19 12.90 -15.86 
Shc1 Y239/Y240 6.63 -9.26 -15.53 
STAT1 Y701 -14.81 3.39 -15.52 
ERK1 Y204 -7.10 4.25 -15.33 
Lyn Pan-specific -16.86 -0.77 -15.15 
IRS1 Y612 -17.52 -22.33 -14.99 
Hsp70 Pan-specific -23.91 5.08 -14.86 
MEK6 Pan-specific -31.93 -8.54 -14.51 
STAT1 S727 -1.51 -19.60 -14.21 
p38a MAPK Pan-specific -2.15 -6.88 -13.89 
DUSP11 Pan-specific 3.57 -4.23 -13.85 
p53 S37 -3.75 18.78 -13.46 
MEK1 T292 -25.19 -12.15 -13.31 
Akt1 (PKBa) Y326 -13.01 8.74 -12.91 
MEK1 T386 1.69 18.28 -12.52 
MEKK-NT Pan-specific 19.08 -22.53 -12.46 
Akt2 (PKBb) Pan-specific -7.32 -8.24 -10.41 
DUSP12 Pan-specific 24.61 0.41 -10.34 
Grp75 Pan-specific 8.49 23.62 -10.32 
CDC42 Pan-specific 8.39 -16.64 -9.50 
NFKB p65 S536 -17.17 -9.00 -8.91 
MAPKAPK2 T334 -5.47 1.76 -8.84 
eIF4E S209 -26.33 -8.69 -8.30 
IRS1 S639 25.76 -7.85 -7.58 
VEGFR2 Y1214 -17.76 1.94 -7.49 
*List of C70-TGA and/or 50 μM H2O2 affected antibody microarray results (duplicate spots).   
Site of phosphorylation is given after protein name.  %CFC, percent change from control. 
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Table 2. List of Proteins affected by TGA and/or 50 μM H2O2. (Cont’d) 
 
Target Protein Phospho-site %CFC                
50µM H2O2 
%CFC            
1µg/ml TGA 
%CFC                
50µM 
H2O2/1µg/ml 
TGA  
STAT5 Y694 5.89 -3.48 -7.39 
ERK1/2 Pan-specific -1.38 15.75 -7.23 
Shc1 Y349 7.31 -12.87 -7.12 
Grp78 Pan-specific -15.23 2.51 -6.98 
CDC7 T376 10.57 -9.35 -6.95 
p38b MAPK Pan-specific 17.02 4.14 -6.92 
Hsp27 S15 -13.24 1.70 -6.58 
DUSP2 Pan-specific 0.10 5.41 -6.38 
p38g MAPK Pan-specific 9.12 10.65 -6.33 
ERK1/2 Y204+Y187 -13.39 13.87 -6.20 
MAPKAPK5 T186 -13.15 1.10 -5.75 
p38d MAPK Pan-specific 10.32 -3.14 -5.48 
Tubulin Pan-specific -23.20 -13.86 -2.97 
PTEN Pan-specific 0.69 -10.11 -2.19 
p38a MAPK T180+pY182 2.08 -4.54 -2.03 
ERK5 Y221 -15.95 2.57 -1.07 
PTEN S380/T382/T383 5.12 11.06 -0.63 
MELK Pan-specific 21.32 -7.25 -0.47 
*List of C70-TGA and/or 50 μM H2O2 affected antibody microarray results (duplicate spots).   
Site of phosphorylation is given after protein name.  %CFC, percent change from control. 
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Table 2. List of Proteins affected by TGA and/or 50 μM H2O2. (Cont’d) 
Target Protein Phospho-site %CFC                
50µM 
H2O2 
%CFC            
1µg/ml 
TGA 
%CFC                
50µM 
H2O2/1µ
g/ml 
TGA  
MKP2 Pan-specific -14.65 -8.47 -0.26 
A-Raf Y302 2.26 -1.66 0.52 
ERK1 T202+Y204 -19.55 -0.63 1.40 
mTOR S2448 26.83 -2.57 1.64 
Hsp27 S78 -12.97 6.30 1.92 
4E-BP1 Pan-specific -8.86 -8.65 2.28 
eIF4B S422 -8.33 3.82 2.35 
IRS1 S312 9.82 -10.69 2.42 
Jun Y170 -18.80 22.47 2.50 
eIF4E Pan-specific -16.50 -24.60 3.08 
MEK4 Pan-specific -3.47 16.26 3.25 
ERK4 S186 7.79 -10.52 3.34 
MEK2 Pan-specific 13.54 37.62 3.45 
ERK1 Y204+T207 12.39 37.78 4.19 
Akt1 (PKBa) Pan-specific 5.49 -8.91 4.44 
DUSP5 Pan-specific -4.35 1.25 4.98 
STAT6 Pan-specific -20.18 56.85 5.31 
NFKB p65 S529 -1.47 13.79 6.20 
4E-BP1 T45 -37.41 -0.54 6.53 
JNK 1/2/3 T183/Y185 17.77 -1.93 6.54 
GADD 153 (CHOP) Pan-specific 45.40 6.15 6.60 
Hsp27 S86 -6.56 2.20 7.22 
ERK5 Pan-specific -9.92 0.17 7.24 
GroEL Pan-specific -3.44 -5.42 7.83 
ALK Y1507 37.88 30.23 8.92 
MEKK2 Pan-specific 9.41 0.02 8.93 
PI3-Kinase Pan-specific -28.91 -6.15 9.49 
MEK1 + B23(NPM) S217+S221 -9.03 60.75 9.54 
STAT5A Pan-specific -22.59 -9.74 10.18 
AMPKa2 S377 21.79 2.54 10.93 
DUSP3 Pan-specific 35.71 20.45 11.25 
VGFR1 Pan-specific 8.71 4.65 11.40 
MDM2 S166 -11.96 6.06 11.70 
MEK3/6 S189/193/S207/211 18.28 8.63 12.06 
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p21 CDKI1 Pan-specific -8.01 25.47 12.30 
VEGFR2 Y1059 -7.29 15.67 12.96 
*List of C70-TGA and/or 50 μM H2O2 affected antibody microarray results (duplicate spots).   
Site of phosphorylation is given after protein name.  %CFC, percent change from control. 
 
 
Table 2. List of Proteins affected by TGA and/or 50 μM H2O2. (Cont’d) 
 
Target Protein Phospho-site %CFC                
50µM H2O2 
%CFC            
1µg/ml 
TGA 
%CFC                
50µM 
H2O2/1
µg/ml 
TGA  
Insulin Receptor b Pan-specific -11.86 2.82 13.23 
p38a MAPK T180/Y182 -20.13 -7.00 13.53 
MKK7 Pan-specific -10.39 66.43 13.80 
DUSP7 Pan-specific 27.15 -6.63 13.84 
DUSP1 (MKP1) Pan-specific 18.33 -2.90 13.89 
JNK2 Pan-specific -11.49 -9.01 13.91 
NFKB p65 (Rel A) S276 -12.14 -8.01 15.27 
ERK1 S74 -5.29 13.82 15.95 
MEK3 Pan-specific 21.91 88.77 16.50 
MAPKAPK2 T222 -7.60 22.01 16.62 
MKK3 Pan-specific 1.82 -7.73 16.76 
ERK5 T219+Y221 0.42 13.40 17.29 
MEK1 Pan-specific 2.91 6.35 17.71 
STAT2 Y689 -12.12 4.87 17.72 
Jun S243 11.96 0.91 17.73 
MEK5 Pan-specific 27.10 -6.63 18.12 
ERK2 Pan-specific 11.59 9.82 18.18 
CDK1 Pan-specific 9.70 -3.42 18.71 
p70 S6K T229 6.35 17.92 19.13 
eIF2a S52 1.57 3.24 19.62 
STAT5B Pan-specific 10.19 1.49 20.73 
A-Raf Pan-specific 28.82 8.36 22.08 
p27 Kip1 Pan-specific 13.58 64.07 23.06 
VGFR3 Pan-specific -2.33 16.83 23.93 
ERK5 T218+Y220 -4.01 20.48 25.31 
NFkappaB p50 Pan-specific -12.50 -0.64 25.84 
DUSP9 Pan-specific 24.46 6.00 27.41 
VEGF-C Pan-specific 7.71 10.18 27.45 
CREB1 S133 24.96 4.94 27.54 
DUSP6 Pan-specific 13.61 1.02 27.83 
NFkappaB p65 Pan-specific -3.43 17.28 29.72 
ERK1 T207 21.19 31.45 30.62 
ERK1 Pan-specific 14.95 18.67 30.84 
MKK6 Pan-specific 15.97 4.61 32.28 
STAT1 Pan-specific -4.96 43.28 34.17 
STAT3 Pan-specific -16.95 7.78 34.59 
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ERK3 Pan-specific 3.51 10.60 36.26 
MKK3 Y230 -0.64 -14.56 37.98 
Wee1 Pan-specific 33.47 57.59 40.52 
Hsp105 Pan-specific 30.73 81.93 41.13 
DUSP4 Pan-specific 28.29 7.31 41.20 
*List of C70-TGA and/or 50 μM H2O2 affected antibody microarray results (duplicate spots).   
Site of phosphorylation is given after protein name.  %CFC, percent change from control. 
 
 
Table 2. List of Proteins affected by TGA and/or 50 μM H2O2. (Cont’d) 
 
Target Protein Phospho-site %CFC                
50µM 
H2O2 
%CFC            
1µg/ml 
TGA 
%CFC                
50µM 
H2O2/1µg/
ml TGA  
Jun T91 14.50 20.12 42.22 
MKK4 Pan-specific 25.57 8.86 42.99 
mTOR Pan-specific 29.19 9.25 43.74 
eIF4G S1232 11.01 43.61 44.99 
eIF2a Pan-specific -0.12 21.32 46.50 
DUSP8 Pan-specific 48.35 14.62 48.36 
SODD Pan-specific 57.80 14.61 49.15 
ASK1 Pan-specific 31.91 21.90 49.63 
CREB1 S129/S133 -2.39 23.31 53.17 
JNK1 Pan-specific 49.99 -13.17 58.46 
p53 S33 44.56 7.53 61.82 
Fos Pan-specific 76.56 25.02 64.69 
STAT2 Pan-specific 71.08 57.53 65.77 
VGFR2 Pan-specific 51.76 11.58 69.88 
STAT4 Pan-specific 17.82 40.31 79.30 
ATF2 S94/S112 -4.99 75.33 86.27 
Grp94 Pan-specific 115.25 9.84 119.65 
*List of C70-TGA and/or 50 μM H2O2 affected antibody microarray results (duplicate spots).   
Site of phosphorylation is given after protein name.  %CFC, percent change from control. 
 
 
 
 
